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1a. Abstract 
Necrotizing Soft Tissue Infection (NSTI) is a fulminant disease of the deeper layers of 
skin and subcutaneous tissue that is mostly caused by the gram-positive pathogen 
Streptococcus pyogenes. Due to the aggressive and fast development, NSTIs require 
intensive care with rigorous medication, ablative surgery and adjunctive therapies 
like intravenous immunoglobulin administration (IVIG). Considering the discussed 
functional effects of an IVIG treatment, it was hypothesized that a lack of protective 
antibodies against the causative bacterial pathogen and its specific spectrum of 
secreted toxins represents a risk factor towards the development of a severe NSTI. 
To address the role of bacterial and exotoxin-specific antibody titers during 
the NSTI pathogenesis, a serologic approach was pursued using plasma samples and 
bacterial isolates of clinical NSTI cases and non NSTI control cases of severe skin and 
tissue infections that did not develop a necrotic stage, collected during the early and 
late stage of infection. The antibody mediated protection potential of the collected 
plasma samples against the corresponding bacterial pathogens was measured by an 
established Opsono-Phagocytosis assay. It was obvious that the adaptive immune 
system of all analysed NSTI patients was not able to provide efficient protection 
against the corresponding bacterial isolate during the early stage of infection, 
although an applied IVIG treatment was able to compensate this susceptibility. This 
was in contrast to the results obtained with the non NSTI control cases wherein all 
plasma samples mediated effective opsonisation and bacterial killing. The analysis of 
the patient plasma samples towards antibody mediated protection against pathogen 
specific exotoxin sets identified by a multiplex PCR screening was addressed with an 
established ELISA system in combination with specialized functional assays. This 
approach not only confirmed the crucial role of the adaptive immune system during 
the confrontation with S. pyogenes, it also demonstrated the potential of an IVIG 
treatment to compensate this stage of immunologic susceptibility. 
The presented data clearly illustrate that a lack of protective antibodies 
against the invading bacterial pathogen and its specific set of secreted toxins 
represents a significant risk factor for the development of a severe NSTI. 
Additionally, it could be shown that the applied IVIG treatment is able to 
compensate this serologic susceptibility. Consequently, the presented work not only 
provided a valuable insight into the complex interactions during the pathogenesis of 
an NSTI, it also represents a first step towards the development of a specialized, 
more targeted treatment strategy. 
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1b. Zusammenfassung 
Nekrotisierende Weichgewebeinfektionen (NSTIs) sind schwere Entzündungen der 
tieferen Schichten der Haut und des subkutanen Gewebes meist hervorgerufen 
durch den Gram-positiven Erreger Streptococcus pyogenes. NSTIs erfordern eine 
aggressive medizinische Behandlung mit erheblicher Medikamentierung, ablativer 
Chirurgie und dem Einsatz spezialisierter Therapieformen wie der intravenösen 
Verabreichung von Immunglobulinen (IVIG). Unter Berücksichtigung der 
beschriebenen funktionellen Wirkung einer IVIG-Behandlung wurde die Hypothese 
aufgestellt, dass ein Mangel an protektiven Antikörpern gegen den ursächlichen 
bakteriellen Erreger und das ihm inhärente Spektrum sekretierter Toxine einen 
Risikofaktor darstellt, der zur Entwicklung einer schweren NSTI beiträgt. 
Um die Rolle von bakterien- und exotoxinspezifischen Antikörpern während 
der Pathogenese einer NSTI zu untersuchen, wurde eine umfassende serologische 
Studie durchgeführt, bei der Plasmaproben und bakterielle Isolate sowohl klinischer 
NSTI Patienten, als auch einer Kontrollgruppe von Patienten mit schweren Haut- 
und Gewebeinfektionen, die sich nicht zu einer NSTI entwickelten, analysiert. Die 
Plasmaproben wurden mit Hilfe von Opsono-Phagozytose-Experimenten auf ihr 
Potential untersucht, die spezifischen bakteriellen Erreger mit Hilfe von Antikörpern 
für eine effektive Immunantwort zu markieren. Dabei konnte gezeigt werden, dass 
das adaptive Immunsystem aller analysierten NSTI Patienten nicht imstande war, 
einen wirksamen Schutz gegen das jeweilige Bakterienisolat während der frühen 
Phase der Infektion zu gewährleisten, wobei eine IVIG-Behandlung diesen Mangel 
kompensieren konnte. Demgegenüber waren die Antikörper in den Plasmaproben 
der Kontrollgruppe in der Lage, eine effektive Opsonisierung der Bakterien zu 
vermitteln. Die Analyse der Plasmaproben in Hinsicht auf einen 
antikörpervermittelten Schutz gegen erregerspezifische Exotoxinkombinationen, die 
durch eine Multiplex-PCR Analyse identifiziert wurden, konnte mit Hilfe eines 
etablierten ELISA-Systems in Verbindung mit spezialisierten funktionellen 
Experimenten adressiert werden. Dieser Ansatz bestätigte die entscheidende Rolle 
des adaptiven Immunsystems während der Konfrontation mit dem Erreger 
S. pyogenes und demonstrierte das Potenzial einer IVIG-Behandlung, den 
beobachteten Mangel an schützenden Antikörpern erfolgreich zu kompensieren. 
Die vorgestellten Daten zeigen, dass ein Mangel an protektiven Antikörpern 
gegen den bakteriellen Erreger und sein Spektrum an Toxinen einen bedeutenden 
Risikofaktor für die Entwicklung einer schweren NSTI darstellt und dass die 
verabreichte IVIG-Behandlung in der Lage ist, diesen Risikofaktor zu kompensieren. 
Damit trägt die vorliegende Arbeit nicht nur zum Verständnis der komplexen 
Wechselwirkungen bei der Pathogenese einer NSTI bei, sondern stellt auch einen 
ersten Schritt bei der Entwicklung einer spezialisierten, gezielteren 
Behandlungsstrategie für nekrotisierende Weichgewebeinfektionen dar. 
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2. Introduction 
2.1 Necrotizing Soft Tissue Infections (NSTI) 
Necrotizing Soft Tissue Infections like Necrotizing Fasciitis (NF) are life-
threatening infections of the deeper layers of skin and subcutaneous tissue, 
spreading across the fascia1. These infections were first reported by Jones in 1871 and 
were named as ‘Hospital gangrene’ at that time. Later in 1951, Wilson observed 
inflammation and necrosis of the subcutaneous tissue and fascia with and without 
cutaneous gangrene and introduced the term ‘Necrotizing Fasciitis’ for such 
infections2. Even though it can impinge any part of the body, it is most commonly 
seen in the lower extremities3. Generally, cases of NSTI without prompt diagnosis 
may lead to 100% mortality, therefore, early diagnosis, along with aggressive 
surgical treatment, are critical factors for a reduction of the mortality rate. 
Unfortunately, it is often difficult to diagnose NF due to its close similarities with 
cellulitis during early days of infection. Patients are erroneously treated for cellulitis 
until the site of infection turns black, becomes necrotic and starts to degrade 
rapidly4. Antibiotic therapy and early surgical debridement are mandatory for 
ensuring a decreased mortality rate; that generally varies from 25-35% but can even 
go as high as 73%5. NSTI is thought to be associated with some risk factors including 
diabetes, chronic diseases, immunosuppressive drugs, malnutrition, age more than 
60 years, intravenous drug misuse, peripheral vascular disease, renal failure, 
underlying malignancy and Obesity, but also with small wound infections or 
trauma4. Various pathogens have been associated with Necrotizing Fasciitis and thus 
NF can be either a poly-microbial or mono-microbial infection (2.1.1).  
2.1.1 Pathogens associated with Necrotizing fasciitis 
NF is not associated to a specific pathogen, rather can be caused by a wide spectrum 
of aerobic, anaerobic or mixed flora. Due to this diverse etiology, NF can be 
classified into three distinct types: Type I, II and III. A Type I infection of NF refers 
to poly-microbial infections as it is caused by a combination of anaerobic bacteria 
and facultative anaerobic bacteria, such as enterobactericeae and streptococci other than 
group A. In almost all cases of Type I NF, one anaerobic organism was cultured in 
combination with a facultative anaerobe. Type II are mono microbial infections 
largely dominated by Streptococcus pyogenes (Group A Streptococcus), therefore this 
type is also known as ‘Streptococcal gangrene’. In some cases Staphylococcus aureus 
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can also be responsible for a Type II NF. Lastly, Type III is known as ‘gas gangrene’, 
due to the production of gas at the site of infection as a result of glucose 
fermentation6. It is generally associated with an infection of Clostridium species; 
especially by Clostridium myonecrosis, Clostridium perfringens, Clostridium septicum and 
Clostridium novyi. Irrespective of the pathogen causing NF, there are some common 
clinical manifestations. (2.1.2)  
2.1.2 Clinical Manifestations of Necrotizing fasciitis 
Necrotizing Fasciitis is a rapidly progressing insidious disease and is therefore 
difficult to diagnose. The mortality rate is directly dependent on the time spent for 
the identification of NF. The longer is the time frame, the higher is the predicted 
mortality rate. Hence, early diagnosis is a crucial factor in reducing the mortality rate 
of NF. As the disease progresses, distinct signs and symptom of the disease appear. 
Initial phase (Approximately day 1-2) is generally demarcated by local pain, swelling 
and erythema. At this stage, it mimics closely to cellulitis but the necrotizing 
infection is located in deeper skin layers therefore difficult to recognize. Unlike 
cellulitis, the margins of infection are poorly defined, with tenderness extending 
beyond the apparent area of involvement. On day 2-4, the infected area develops 
tense edema, extending beyond the margin of erythema. The affected skin area 
becomes dis-colored, progressing to grey/black necrotized skin to tear off (skin 
abrasion and avulsion of the sub cutaneous region). Pain sensation may progress 
from intense tenderness to anesthesia as the nerves are destroyed. If there is an open 
wound, probing the edges with a blunt instrument produces easy dissection of the 
superficial fascial planes well beyond the wound margins. Till day 4-5, hypotension 
and toxic shock develops and the patient becomes confused and apathetic.  
2.1.3 Diagnostics of necrotizing fasciitis 
Establishment of fast diagnosis for NF is not easily possible, since it resembles 
closely to cellulitis during early days. Resultantly, a delayed identification lead to a 
dramatic increase in the prognosticated mortality rate. Therefore, a proper test is 
essential for its confirmation and thence treatment. Unfortunately, there is no 
definitive test available and therefore, surgery is requisite to confirm or exclude the 
possibility of NF. However, initial standard clinical tests are performed for 
diagnosing NSTI as mentioned below. 
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 Blood tests: Usually, patients with NF infections show abnormal blood chemistry 
due to systemic effects of infection. As there is excessive involvement of 
inflammatory responses, concentration of C-reactive protein (CRP) (>16 mg/ml) 
and White blood cell count (>15.4 x 109/L) are elevated in NSTI patients. In 
addition, blood samples may show acidosis, leukocytosis, altered coagulation 
profile, hypo-albuminaemia, and abnormal renal function7. Other changes in 
blood parameters, such as reduced serum sodium (<135 mmol/L), raised CK level 
(> 600 U/L) and urea levels (>18 mg/dL) can also be observed.  
 Bedside finger test: Surgical interventions to explore NSTI affected soft tissue is 
considered to be a reliable option by the physicians and should be performed as 
soon as possible. For this test, local anesthesia is executed and an incision of 2 cm 
is made into the deep fascia. Gentle probing with the index finger is performed to 
screen for any signs of NF. Some of the signs include lack of bleeding, 
malodorous "dishwater pus", and lack of normal tissue resistance to blunt finger 
dissection. Alternative procedures are taking a bedside incisional biopsy of the 
affected fascia and perform cryo-sectioning and Gram staining. 
 
 Microbiology: Includes blood culturing, wound swabs, Gram staining and 
culture of affected tissues (from surgery or biopsy). Fungal culturing is important 
in immunocompromised and trauma patients. Since classical microbiological 
examinations take few days for confirmation for NSTI and its causative 
pathogen, it generally delays the targeted therapeutic interventions, thereby 
increasing the prognosticated mortality rate. 
 
 Radiology: Plain X-ray or Computed tomography (CT) scan is able show 
accumulation of soft tissue gas8. Magnetic resonance imaging (MRI) scans can 
show the extent of tissue involvement9, but may not be accurate and should not 
delay a surgery. Similarly, Ultrasound has also been used to show subcutaneous 
gas10. However, there are many possibilities of false positives and therefore 
Radiological techniques are not the first/preferred choice of Physicians in initial 
diagnostics of NF. 
 
 Other tests: Tissue oxygen saturation measured by near-infrared spectroscopy 
can be used as a bedside test. A cut off value of tissue oxygen saturation reading 
of less than 70% is confirmation of NSTI11. 
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The development of an NSTI is interplay between the host immune system and the 
invading pathogen. Delays in the identification can significantly increase the 
prognosticated mortality rate. To identify risk factors for the disease development, it 
is important to understand the role of the host immune system and the mechanisms 
through which the pathogen counteracts it. It is a crucial step for the development of 
specific diagnostics and therapeutics.   
2.2 The role of the immune system during necrotizing fasciitis 
The human immune system comprises an enormous variety of cells and molecules 
that specifically recognize and eliminate foreign invaders. These cells and molecules 
act together in a dynamic network for successful elimination of pathogens. 
Functionally, the immune system can be divided into two major but related 
activities: Recognition and Response. Recognition by the immune system is performed 
by exquisite chemical differences that distinguish self from non-self and thus 
identifies an invading pathogen. Once it is recognized as a foreign, the immune 
system recruits ‘always ready and available’ cells and molecules that escalate an 
appropriate response, called an effector response, to eliminate or neutralize the 
foreign organism (Innate Immune System). If the pathogen eludes the capture by the 
innate immune system, or if there is an antigenic confrontation, the second part, 
called the Adaptive Immune System, is activated that constitutes a set of specialized 
cells recruited which identifies the pathogen, eliminate it and retains memory of the 
encounter for future (Memory Response). Later exposure to the same foreign 
organism induces a memory response that is described as more rapid and 
heightened immune reaction to eliminate the pathogen. In this way, the immune 
system is able to convert the initial recognition event into a variety of effector 
responses, each one being exclusively suited for eliminating a particular type of 
pathogen.  
2.2.1 Functionality of the innate immune system during Necrotizing Fasciitis 
The innate immune system represents the first line of defense against invading 
organisms as most components of it are present before the onset of infection and 
constitute a set of disease-resistance mechanisms that are not specific to a particular 
pathogen but include cellular and molecular components that recognize classes of 
molecules peculiar to frequently encountered pathogens. For a proper functioning of 
the immune system, it requires three sets of components: A recognition system to 
identify the pathogen, a disposal system to kill/eliminate the pathogen and a 
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communication system to coordinate activities of various recognition and disposal 
elements. 
Generally, the Physical and Anatomical Barriers of the body (like the skin) act as a very 
effective obstruction against invasion by most pathogens. However, pathogens like 
Streptococcus pyogenes can enter the host generally through wounds/ burns/ scratches 
or abrasions that disrupt the continuity of the skin. Once the physical barriers are 
broken and S. pyogenes successfully enters the host, the Physiological barriers 
contribute in its recognition and elimination through various soluble and cell 
associated molecules. Many of these molecules of the innate immune system have 
the property of Pattern Recognition, the ability to recognize a given class of 
molecules. Because some surface molecules are unique to S. pyogenes that are not 
present on the surface of the host cells, the innate immune system is able to 
immediately recognize and combat the invader. Molecules of Pattern recognition 
could be soluble, like the complement system (described later) or cell surface 
receptors, for example, Toll like Receptors (TLRs). TLRs are single, membrane 
spanning, non-catalytic receptors, usually localized on the surface of cells of innate 
immune system (like macrophages or polymorpho-nuclear cells, PMNs) that detect 
the presence of microbial pathogens via the conserved microbial structures called 
pathogen-associated molecular patterns (PAMPs)12. TLRs can be differentiated into 
distinct types, based on their location and recognizing target, including TLR1-13, 
although TLR 11-13 are not described in humans. Different TLRs respond to 
different PAMPs, for example, TLR2 functions as a receptor for lipopolysaccharide 
(LPS), an integral component of the outer membranes of gram-negative bacteria13 
and for Lipoteichoic acid (LTA), a major constituent of the cell wall of gram positive 
bacteria like S. pyogenes. The exact mechanistic action of TLRs in the recognition of   
S. pyogenes is not known, however some studies in mice suggest that S. pyogenes is 
initially recognized by TLR2 and subsequently by TLR13. However, phylogenetic 
analyses revealed that TLR13 occurs only in few mammals, including mice and rats, 
which are naturally resistant against S. pyogenes14. Hence, the presence of TLR13 in 
mice and not in humans has functional consequences for the recognition of S. 
pyogenes in these organisms. The interaction of TLRs with their target motifs initiates 
a cascade of intracellular signaling events that results in the production of 
proinflammatory cytokines (TNF-α, IL-l, IL-8), chemokines, and costimulatory 
molecules that are important to coordinate the host defenses12. These molecules 
attract neutrophils and macrophages, the main participants of the innate immune 
response that help in eradication of the bacteria at the site of infection through 
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Phagocytosis: a process by which bacteria/solid particles are engulfed into the cell 
through membrane invaginations (pseudopodia) and formation of vesicles called 
‘phagosomes’, that subsequently fuse with lysosomes to form a ‘Phagolysosome’ 
where the bacteria are killed by reactive oxygen and nitrogen species (ROS/RNS) 
and digested by various proteases and DNases in a bacteriostatic acidic environment 
(Figure 2.1).  
 
Figure 2.1: Schematic illustrating the different steps in phagocytosis of bacteria by professional 
phagocytic cells of the innate immune system. (1) The bacteria get attached to the membrane of the 
phagocytic cell, which induces invagination by pseudopodia. (2) The bacteria are ingested into the cell, enclosed 
in a Phagosome. (3) The phagosome fuses with a lysosome that contains more than 50 digestive enzymes and 
forms a phagolysosome. (4) Bacteria are killed by reactive oxygen and nitrogen species (ROS/RNS) and 
digested by various proteases and DNases in an acidic environment (5) Degraded bacterial components are 
secreted from the cell. [Modified from Kuby, 5
th
 Edition] 
Tissue damage due to a wound and the subsequent recognition response triggered 
by TLR binding to an invading pathogen usually leads to an “Inflammatory 
response”. The cardinal signs of inflammation can be reflected by three signs: 
 Vasodilation: An increase in the diameter of the blood vessels and nearby 
capillaries occurs along with the constriction of capillaries that carry blood away 
from the affected site, resulting in the engorgement of the capillary network, 
causing tissue redness (erythema) and increased tissue temperature. 
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 Increase in Capillary permeability: High influx of fluids (exudate) containing 
higher protein content than the fluid normally released into the tissue from 
Vasculation leads to tissue swelling (Edema).  
 
 Influx of Phagocytes: Due to increased permeability of capillaries towards the 
tissue, phagocytic cells like neutrophil granulocytes are recruited from the blood 
circulation system and accumulate at the tissue site of infection to attack bacterial 
invaders. Finally, the accumulation of dead immune cells with their digested 
material and fluid forms Pus.  
Once the inflammatory response subsides, most of the developed debris is cleared 
by phagocytic cells of the innate immune system. Subsequently, tissue repair and 
regeneration of new tissue structures begins. As aforementioned, apart from TLR-
associated recognition of pathogens that is receptor based, soluble proteins of 
Pattern recognition, like the Complement system, also play an important role in 
identification and labelling of bacterial invaders for phagocytosis.  
2.2.2 The role of the complement system during necrotizing fasciitis 
The Complement system is a major component of the innate immune system that is 
involved in identification and eradication of pathogens by complement factors that 
aid in opsonization, chemotaxis and killing. The complement system is a general 
term assigned to more than 30 soluble plasma proteins and to a number of cell 
receptors and control proteins found in blood and tissues that support the innate 
and adaptive immune response in recognition and eradication of invading bacteria. 
The complement system can be activated by the classical (Antibody-Antigen 
interactions), alternative (Bacterial Surface), or lectin pathway (Microbial 
carbohydrates). Activation of the complement system by one of the three pathways 
leads to an accumulation of complement opsonins, C3b and C3bi, on the bacterial 
surface thus opsonizing it. Opsonization is a process of ‘labeling’ or ‘targeting’ the 
bacterial cells by the immune system for phagocytosis. The complement system not 
only labels S. pyogenes for disposal by neutrophils, but also leads to formation of the 
Membrane Attack Complex (MAC) that causes a pore formation in the bacterial cell 
membranes. However, the MAC complex is considered to be not very efficient in 
case of S. pyogenes as it is a gram positive bacterium carrying a thick peptidoglycan 
cell wall15.  
Along with the innate immune system and the complement system, second line of 
defense or the Adaptive immune system is activated that boosts the clearance of 
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pathogen by generation of specific antibodies and memory cells that retains memory 
of the encounter for future. 
2.2.3 The role of the adaptive Immune system during necrotizing fasciitis 
The adaptive (or acquired) immunity actively contributes to the recognition and 
selectively eradication of foreign antigens/pathogens. In contrast to the innate 
immune system, which is a broad spectrum defense system, the acquired immune 
system varies according to specific antigenic challenges encountered. An antigen 
(Antibody generator; Ag) can be any structural substance that serves as a target for 
the receptor regions of Immunoglobulins (Ig). Ig are Y-shaped glycoproteins 
produced by differentiated B-cells (activated B-cells/Plasma cells; B-cells that have 
encountered Ag). All immunoglobulins have a common structure consisting of two 
heavy (H) and two light (L) protein chains, with constant (C) and one variable (V) 
regions. Constant regions of heavy chains (CH1, CH2 and CH3; CH4 in case of IgE and 
IgM) or light chain (CL) are connected to the variable regions of Heavy chain (VH) or 
light chain (VL) by protein bonds called Hinges. The heavy and the light chain are 
interconnected to each other by di-sulfide bonds. Additionally, the antibody can be 
horizontally divided into two regions: Fab and Fc. Fab (Fragment antigen binding) is 
the region where an antigen is bound and is composed of one constant and one 
variable domain of each heavy and light chain. The Fc (Fragment crystallizable) 
region, on the other hand, forms the tail region of the antibody which interacts with 
cell surface receptors (Fc receptors) or the complement factors (C1q) to induce the 
immune system (Figure 2.2A).  
 
Figure 2.2: Schematic diagram showing the types of antibodies generated by B-cells of the adaptive 
immune system. (A) General structure of an antibody produced by activated B-cells. Different regions have 
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been demarcated with different numbers. 1: Fab Region, 2: Fc region, 3: Heavy chain (Black bars) with one 
variable (VH) domain followed by a constant domain (CH1), a hinge region and two/three more constant (CH2, CH3 
and CH4) domains, 4: Light chain (Grey bars) with one variable (VL) and one constant (CL) domain, 5: Antigen 
binding site (paratope), 6: Hinge region. (B) Different types of antibodies produced by human B-cells: IgG, IgE, 
IgD are produced and function as monomers. IgM is known to act in pentamers whereas Secretory IgA as 
dimers. The oligo/polymerization of IgM and IgA is done by Junction-chains (orange). The secretory component 
of sIgA has been shown in red [Modified from Kuby, 5
th
 Edition
16
]. 
Antibodies could be differentiated into five different types (Figure 2.2B), based on 
their location of action and type of Ag confronted: 
 IgG: IgG is the main antibody found in human blood, constituting up to 70-80% 
of total Ab16. IgG is able to cross the placenta and therefore be transferred 
(acquired) from mother to newborn. It is widely distributed to the blood and 
tissue and plays a crucial role in combatting S. pyogenes and its secreted toxins in 
local tissue and systemic infections through several mechanisms: (1) Binding to 
pathogen causing their debilitation by agglutination17, (2) coating the surface of 
pathogen, thus activating the complement system via the classical pathway17 (3) 
Binding to exotoxins to neutralize them17.   
 
 IgM: IgM is the type of antibody that is produced during the initial encounter of 
the pathogen with the immune system and actively functions as pentamers, 
thereby aiding in crosslinking and restricting the pathogen from further 
dissemination. Due to its polymeric nature, IgM is difficult to diffuse, but possess 
high avidity. IgM contributes greatly to opsonization by activating complement 
and causing C3b to bind to the antigen16.  
 
 IgA: IgA consists of two types (IgA1 and IgA2) that exist in dimeric form called 
the secretory IgA or sIgA. Secretory IgA plays an important role in mucosal 
immunity and functions as a dimer (made of 2 antibodies), joined together by the 
Junction-chain (J-chain) and are distributed in serum, nasal discharge, breast milk 
and bowel fluid16. The secretory component of sIgA protects it from proteolytic 
enzymes, thus sIgA can survive in harsh environments and provide protection 
against pathogens18.  
 
 IgD: IgD comprises of only 0.25% of the total immunoglobulins and form 
approximately 1% of proteins found in the plasma membrane of B-cells. It plays a 
role in the induction of antibody production16. 
 
 IgE: IgE is believed to be related to immune reactions to invading parasites, and 
has recently become known as a key factor of allergies such as pollinosis16. 
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The Adaptive immune response exhibits four distinct characteristics on 
encountering a pathogen: Antigenic specificity, diversity, immunological memory 
and self/non-self-recognition. Antigenic specificity refers to the ability of the adaptive 
immune system to differentiate exquisite distinctness among antigens. Antibodies 
are able to differentiate between two proteins that vary only in one amino acid19. 
Immunological diversity of the adaptive immune system allows it to identify unique 
structures of millions of pathogens/antigens. Once the immune system has 
responded to a particular antigen, it displays an immunological memory. A second 
encounter with the same antigen would therefore produce a rapid and intensive 
immune reactivity. This attribute helps in the development of a long-term immunity 
to that particular antigen. Finally, the adaptive immune system is able to distinguish 
between self (host) and non-self (foreign)-antigens; thus responding only to the 
foreign molecules. This is an important feature of the adaptive immune system as 
any response to self-antigens could lead to auto-immune diseases.  
Once the pathogen or its fragments/secreted products are recognized, they are taken 
up by professional phagocytic cells, wherein the antigens are broken down into 
peptides/fragments. These fragments are displayed on the surface of an altered self-
cell (antigen presenting cell) bound to MHC (Major Histocompatibility Complex) 
molecules which are subsequently recognized by T-cells in combination with T-cell 
receptors (TCR). MHC class II molecules tend to bind to T-helper cells (TH) that are 
activated once they bind to the MHC-II. Activated TH cells secrete cytokines that 
contribute to activation of B-cells. Activation of B-cells through TH cells is known as 
cell-mediated response16. In contrast, B-cells can also interact with antigens 
independently (humoral response) and differentiate into antibody producing plasma 
cells. These antibodies can bind to antigens and facilitate clearance16. However, all 
different types of immune responses (innate/complement/adaptive) are always 
dependent on each other and the antigen clearance is a coordinated interplay of all 
three.  
The generated antibodies are able to bind to antigens on the surface of bacteria and 
can act as ‘opsonins’ together with factor C3b of the complement system. This 
opsonization increases phagocytosis and hence helps in bacterial clearance. 
Antibody-mediated activation of the complement system induces a localized 
production of immune effector molecules that help in developing heightened 
inflammatory response. C3a, C4a and C5a act as anaphylatoxins that induce mast-
cell degranulation and hence causes vasodilation and extravasation of lymphocytes 
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and neutrophils from the blood into the tissue (Figure 2.3). Other complement 
factors serve as chemotactic factors that attract numerous neutrophils and 
macrophages at the site of infection.  
  
Figure 2.3: Antibody-mediated mechanisms for combating infections by invading bacteria. (1) Antibodies 
neutralize bacterial toxins. (2) Complement activation on the bacterial surface leads to complement-mediated 
lysis of bacteria by MAC. (3) Antibodies and the complement product C3b bind to the bacterial surface, serving 
as opsonins to increase phagocytosis. (4) C3a, C4a, and C5a, generated by antibody initiated complement 
activation, induce local mast cell degranulation, releasing substances that mediate vasodilation and extravasation 
of lymphocytes and neutrophils. (5) Other complement products are chemotactic for neutrophils and 
macrophages. [Taken from Immunology, Kuby 5
th
 Edition
16
] 
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Antibodies are able to boost the host immune system by coating the surface of the 
pathogen, thus activating the complement system via the classical pathway and 
neutralizing bacterial exotoxins. The presence of antibody titers specific for the 
invading bacteria and its set of toxins during early phase of infection can lead to 
faster and efficient eradication of the pathogen.  
Although host-defense mechanisms act at each and every step during bacterial 
invasion, bacteria have evolved strategies to circumvent some of these host defenses. 
Mentioned below is the role of the pathogen, S. pyogenes, in the manifestation of 
necrotizing fasciitis and how its virulence factors intervene in host defense 
mechanism.  
2.3 Role of the pathogen S. pyogenes in the manifestation of NF 
The beta hemolytic Group A Streptococcus (GAS) or Streptococcus pyogenes, belongs to 
the genus Streptococcus of the phylum Firmicutes and is an important human 
pathogen causing wide a spectrum of diseases ranging from mild infections of skin 
and mucosa to severe invasive infections generally associated with high mortality, 
such as necrotizing soft tissue infections and toxic shock syndrome20. Streptococcus 
pyogenes is negative for catalase and oxidase and is facultative anaerobe. Different 
Streptococcus pyogenes strains can be characterized based on various typing methods; 
the most widely used is the emm typing (deciphering the M-protein subtype). The M-
protein was first identified by Rebecca Lancefield who named it “M-protein” 
because of the ‘Matt’ appearance of the colonies due to this surface linked protein. 
Later, it was reported to be involved in pathogenesis and crucial for the virulence of 
S. pyogenes21. M-typing can be performed through amplification and sequencing of 
the emm gene encoding for the M-protein. Till date, around 220 different serotypes of 
M–proteins have been reported. Besides the M-protein, S. pyogenes possess a huge 
array of virulence factors that are detrimental to the host and counteract the immune 
system defenses in various ways (2.3.1).  
2.3.1 Virulence factors of S. pyogenes involved in NF 
The host-defense mechanisms try to combat the pathogen at various stages of 
bacterial invasion and infection. However, S. pyogenes secretes a lot of 
factors/exotoxins to fight back the immune system and thus promoting proliferation 
and dissemination of the bacteria. There are four major stages of bacterial infection: 
Initial entry and attachment to host structures, bacterial proliferation, invasion of 
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host tissue and Toxin-induced damage to host cells; each stage been made successful 
by specific proteins and/or other bacterial components. Initial weak interactions are 
triggered by lipoteichoic acid (LTA) or pili with the cell surface or mucosa of 
epithelial surfaces, leading to bacterial colonization22,23. This initial attachment is 
pursed by stronger binding (carbohydrate and/or protein) between the epithelial cell 
layer and the bacteria. Proteins like the M-protein, SfbI, SfbII and ECM proteins like 
fibronectin are known to be involved in this process24. During these interactions, the 
bacteria already start to proliferate and spread into the host system but during all 
stages (attachment, proliferation and dissemination) they are challenged by the 
innate and adaptive immune system of the host. Different mechanisms developed by 
S. pyogenes that intervene in the immune responses are described below. 
2.3.1.1 Virulence Factors intervening the innate immune response  
The first strategy for a pathogen to evade the host immune system is to not get 
recognized. For this, all S. pyogenes strains are able to surround themselves by a thick 
hyaluronic acid capsule25 that serve dual purpose: (1.) Since hyaluronic acid is a 
natural component of the human connective and epithelial tissue, it provides active 
protection against phagocytosis20 as the host immune system is unable to 
differentiate it from the ‘self’. (2.) The capsule is able to cover most of the potentially 
antigenic structures on the surface of S. pyogenes and thus do not elicit the immune 
response by posing an antigenic challenge to the system. Hyaluronic acid is a linear 
polymer of glucuronic-β-1,3-N-acetylglucosamine, produced by the highly 
conserved hasABC (hyaluron synthase) operon26 and is also an important adhesion 
factor as it binds to CD44 receptors on epithelial cells27. Once the bacteria have 
successfully dodged the initial recognition and reached tissue structures, it produces 
Hyaluronidase (Hyl), an enzyme that cleaves hyaluronic acid and exposes all 
bacterial surface proteins for their function. Additionally, Hyl is also able to digest 
structurally identical hyaluronic acid in human tissue and improves bacterial 
spreading28.  
Once the hyaluronic acid capsule is dissolved, the bacterial cell surface is exposed, 
revealing all surface bound proteins. The M-protein is the most abundant protein 
found on the bacterial surface and is the primary virulence factor of S. pyogenes29. It is 
also one of the most important factors in the initial attachment of the bacteria to 
different human cell types30 and contributes with its antiphagocytic function 
mediated by fibrinogen binding31 to the bacterial survival. The M-protein has a 
hypervariable N-terminus, which is the basis for serological differentiation of 
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different S. pyogenes isolates. Interestingly, immunization with M-protein provides a 
strong protectivity toward Streptococcal infections in mice32. Hence, this protein has 
been the most important candidate for vaccine development strategies. Recently, a 
30 valent vaccine, that covers 26 different M-types, is being tested in Phase-1 clinical 
trials and is seen to generate cross–opsonic antibodies also against non-vaccine 
serotypes of S. pyogenes33.  
As already mentioned, phagocytosis is a crucial mechanism of the host innate 
immune system to eradicate the invading pathogen with the help of professional 
phagocytic cells like Macrophages and Neutrophils. However, S. pyogenes is seen to 
cleverly evade these phagocytic attacks by the following mechanisms: 
 Pore formation in phagocytic cells: Production of Streptolysin O (SLO) and 
Streptolysin S (SLS): The 69kDa streptolysin O (SLO) is a thiol-activated 
cholesterol dependent cytolysin that forms large pores of about 30 nm in 
eukaryotic cell membranes leading to apoptosis34,35. It is reported to cause 
apoptosis in epithelial cells, neutrophils and macrophages36. SLO also aids 
infiltration of superantigens (described later in the chapter) into stratified 
mucosa37. Since SLO is co-transcribed with NAD glycohydrolase, it is thus seen to 
mediate the translocation of NAD glycohydrolase into cells through the pores 
being formed. NAD glycohydrolase modulates the host cell signaling pathways; 
hence assisting in S. pyogenes internalization38. Interestingly, SLO expression is 
noticed to be higher in severe invasive cases when compared to non-invasive 
controls pointing towards their active role in the pathogenesis of S. pyogenes 
during tissue infections39. SLS, on the other hand, is non-immunogenic 
oligopeptide of ~2.8 kDa that is responsible for the hemolytic zone around 
colonies of S. pyogenes when cultivated on blood-agar40. Interestingly, cytotoxic 
effects of SLO and SLS were seen to enhance the virulence of poorly encapsulated 
S. pyogenes41.   
 
 Cleavage of NETs: Production of DNases: In order to promote the entrapment 
and consequent clearance of bacteria, neutrophils are able to release ‘NETs’ 
(Neutrophil Extracellular Traps) that are made from DNA and proteins42.             
S. pyogenes has evolved to produce various DNases that can cleave these NETs 
and thus lead to the escape of the bacteria. One of such DNases is the 
Extracellular streptodornase D (sda1/sdaD). SdaD cleaves the DNA network of 
NETs, thus helping the bacteria from the entrapment and killing43. Recently, it 
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has been reported that sdaD helps the bacterial evasion through by TLR9-
dependent recognition and is done through auto-degradation of CpG rich DNA 
by bacterial DNase44.  
 
 Degradation of Chemokines (IL-8): Production of SpyCEP: SpyCEP (also known 
as ScpC, CepA or Prts) is a subtilisin-like protease secreted by S. pyogenes45 that 
can cleave various chemokines like Interleukin-8 (IL-8), Grap-2 (GRB2- related 
adapter protein 2) and GCP-2 (granulocyte chemotactic peptide-2)46,47. Mature 
SpyCEP is a dimer of 2 subunits of 30 and 150 kDa. A stable interaction between 
both subunits is prerequisite for enzymatic activity of the protease48. 
Interestingly, like SLO, SpyCEP is also seen to be upregulated in invasive 
diseases pointing towards an active role in tissue infection manifestation46. 
 
 Dissolution of Fibrin Clot: Production of Streptokinase (Ska): Another common 
host defense mechanism is to trap the bacteria within a fibrin clot in order to 
block the dissemination of the bacteria. In case of a wound that causes blood 
vessel breakdown, a fibrin clot is formed by the action of the 
protease thrombin on fibrinogen which causes the latter to polymerize to stops 
further loss of blood. When the blood vessel/injury is healing, plasminogen is 
converted to plasmin that dissolves the fibrin clot. S. pyogenes has very cleverly 
utilized this host mechanism for self-defense, by the production of Streptokinase 
(Ska). Ska is a 50 kDa glycoprotein that is an important factor in fibrinolysis as it 
activates plasminogen49. Plasminogen is converted to “activated plasminogen” 
that is structurally plasminogen but functionally plasmin, thereby dissolving the 
fibrin clot thus allowing the bacteria to disseminate50. Interestingly, all strains of 
S. pyogenes are known to secrete streptokinase and are capable for acquisition of 
cell surface plasmin51. However, based on the pathway of cell surface plasmin 
acquisition by S. pyogenes, ska is differentiated into three clusters: Cluster-1, 
which combines with plasminogen to form a complex with plasmin activity; 
Cluster-2a, wherein streptokinase must form complex with plasminogen and 
fibrinogen to form a tri-molecular-complex that exhibits plasmin activity by 
binding to the cell surface by fibrinogen binding receptors and Cluster-2b, which 
forms a tri-molecular-complex (streptokinase-plasminogen-fibrinogen) to exhibit 
plasmin activity by binding to cell surface receptors such as the plasminogen 
binding group A streptococcal M-like proteins (PAMs)51 
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 Degradation of antimicrobial peptides: Production of SpeB: Streptococcal 
pyogenic toxin B (SpeB) is a broad spectrum cysteine protease released by most 
of the isolated S. pyogenes strains52 that is seen to degrade anti-microbial peptides 
produced against the pathogen. Although almost all (<99%) isolated strains carry 
this gene in their genome, there is a considerable difference observed in the 
expression levels53. SpeB is initially produced as a 40kDa zymogen which is self-
cleaved to generate a 23 kDa mature form54. Loss of the speB gene is a crucial 
factor for conversion of a local infection causing an S. pyogenes strain to be 
invasive. As SpeB is a broad spectrum protease, it also cleaves bacterial virulence 
factors.  
 
 Interruption of complement activation: Production of SIC: Another aspect of the 
innate immune system is its interaction with the complement system to activate 
the Membrane Attack Complex (MAC). However, the streptococcal inhibitor of 
complement (SIC), a highly polymorphic 31 kDa protein, is secreted by               
S. pyogenes and interfere with the formation of the MAC by constraining the 
interaction of complement complex C5b67 with the bacterial cell membrane55. It is 
also reported to inhibit other molecules of immune system like human 
cathelicidin LL-37, α-defensins, secretory leukocyte protease inhibitor and 
lysozyme56.  
All these mechanisms of combating the attack of phagocytic cells of the innate 
immune system like neutrophils have been illustrated below (Figure 2.4) 
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Figure 2.4: Virulence factors of S. pyogenes that interfere the cellular innate immune response by 
Neutrophils. Streptococcus pyogenes has evolved various defense mechanisms that intervene the innate and 
adaptive immune response by disabling professional phagocytic cells like neutrophils. (1) S. pyogenes strains are 
surrounded by Hyaluronic Acid Capsule that masks antigenic structures on the bacterial surface and resists 
Opsonization. (2) S. pyogenes secretes SIC (Streptococcal Inhibitor of Complement) that binds to Anti-microbial 
peptides (AMP) and constraints the interaction of complement complex C5b67. (3) SdaD/Sda1 is a DNase 
secreted by S. pyogenes that breakdown Neutrophil Extracellular Traps (NETs). (4) SLO or Streptolysin O is an 
active pore forming enzyme that punctures the cell membrane of neutrophils and other host cells to lead them 
towards Apoptosis. (5) SpyCEP is a subtilisin-like protease secreted by S. pyogenes that can cleave various 
chemokines like Interleukin-8. Lastly (6) Streptokinase (Ska) actively participates in fibrinolysis as it activates 
plasminogen to exhibit plasmin activity, that dissolves the fibrin clot thus free the bacteria for spreading. [Modified 
from Cole et al., 2010
57
] 
 
The host immune system is able to eliminate an infection though the interplay of 
innate immune system, the complement system and the adaptive immune system. 
The Adaptive immune system is more targeted towards the pathogen due to 
production of antibodies. However, S. pyogenes has developed mechanisms that can 
assist in its efficiently escaping the adaptive immune response.   
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2.3.1.2 Virulence Factors intervening the Adaptive immune system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
B-cells are directly or indirectly (with help of TH cells) activated to produce specific 
antibodies against antigens presented by the invading pathogens. These antibodies 
help in opsonization and therefore killing of bacteria by specialized phagocytes like 
neutrophils. Out of all types, IgG is the major form of antibodies produced against 
bacterial infections. S. pyogenes secretes IgG endopeptidase (IdeS; also known as 
Mac, MspA), a cysteine protease, that specifically cleaves human immunoglobulin G 
(IgG)58. It is a homologue of human leukocyte β2 integrins which are reported to 
inhibit the activation of neutrophils and production of reactive oxygen species by 
binding CD16B (a low-affinity Fc receptor)56. Two different variants of Mac have 
been described: Complex-I and complex-II, that differ in amino acid level (amino 
acids 112 to 205)59. Complex-I wields their function through proteolytic cleavage of 
IgG58; whereas Complex-II, which is a weaker endopeptidase, blocks interaction of 
the FcγIIIb receptor; thus inhibiting phagocytic killing58,59.  
Antigen presentation and antibody activation are complex mechanisms of the host 
immune system to elicit a response against any foreign structure or pathogen that is 
potentially harmful. Specific receptors for antigen recognition are situated on T-cell 
surfaces called T-cell Receptors (TCR) and on antigen presenting cells (APC). 
Generally, an antigen is cleaved in the lysosome into smaller fragments and is then 
displayed by the antigen presenting cells (APC). These antigen fragments finally 
interact with T-cell that carries a specific αβ TCR having constant and variable 
regions. The selectivity of a TCR to any conventional antigen mainly depends upon 
the variable regions: Vβ, Dβ, Jβ, Vα and Jα60. After binding to a specific TCR, the 
antigen induces a signal transduction and biochemical changes in the T-cell that 
activates it, which then proliferates to generate definite subpopulations of T-cells 
with peculiar variable regions specific to this particular antigen. Unlike the 
conventional antigens, superantigens can bind and stimulate enormous sub-
population of T-cells (Figure 2.5) via the variable region of β chain (Vβ elements)61.  
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Figure 2.5: Differences in the receptor binding activity of a conventional antigen (Ag) and a superantigen 
(SAg). The Ag binds to a TCR via MHC-II receptors on the antigen presenting cells, whereas, a SAg bind to the 
T-cells via the variable β region, leading to non-specific stimulation of large number of T-cells. It should also be 
noted that different SAgs activate different Vβ subtypes [Modified from Streptococcal Superantigens
62
]. 
S. pyogenes secrete a number of different Streptococcal pyogenic exotoxins (SPEs), 
that share sequence similarity of about 17-48% , nevertheless are structurally 
related20,63. These exotoxins belong to the family of ‘Superantigens’ (SAgs)64. SAgs are 
small, but highly mitogenic protein molecules that bind to Major Histocompatibility 
Complex (MHC) class II receptors and TCR molecules leading to a co-stimulation of 
large number of T-cells65. They are known to bind MHC class II outside the peptide 
groove and to CDR2 and HV4 regions on TCR Vβ chains66. These superantigens are 
seen to bind laterally to the βV region and hence cause massive cytokine release61. 
Several SAg genes are located on mobile DNA elements, such as bacteriophages, 
integrated in the bacterial genome67 and hence, are more likely to be genetically 
transferred among different Streptococcal species68. 
Binding of SAg to the T-cell receptor triggers biochemical changes in the cell that 
leads to non–specific activation of a copious amount of T-cells and release of 
inflammatory cytokines like IL-6 and IL-8. Interestingly, these molecules give an 
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edge to the pathogen by allowing it to circumvent the induction of specific adaptive 
immune response of the host. Superantigens are seen to deter the immune system by 
one of the three mechanisms: First, its capability to induce SDCC (Superantigen-
Dependent Cellular Cytotoxicity) that eradicates cells hindering SAg-activated T-cell 
proliferation. Production of IL-8 and other inflammatory cytokines worsens the 
situation for the host, thus enhancing SDCC. Eradication of MHC-II expressing cells 
may also lead to anergy and further incapability of T-cell stimulation. Second, 
massive production of cytokines and proinflammatory chemokines may lead to 
specific apoptosis of T-cells carrying definite Vβ binding site for that Superantigen. 
Lastly, activation of nonspecific T-cells helps in “distracting” the host immune 
system, thus diverting the attention from a centered and specific immune response 
toward the pathogen.  
Understanding the host immune responses and bacterial virulence mechanisms is an 
important aspect of applying therapeutic interventions in treating a disease. Below 
mentioned are few ways that are generally used by physicians to treat NF.  
2.4 Therapeutic interventions to treat NF 
Necrotizing Fasciitis is a rapidly progressing disease. Any delay in initiating suitable 
treatment causes significant increases in mortality rates. Once an NF is diagnosed, 
different specialized therapeutic treatments are provided depending on the severity 
and the site of infection.  
2.4.1 Antibiotics and surgery 
The first step in the treatment of NF is the administration of empirical antibiotics for 
which the causative pathogen is sensitive to. Till the time the pathogen is being 
identified through microbiological testing, initial antibiotics are generally broad 
spectrum, so as to cover both aerobic and anaerobic bacteria. The maximum doses 
given for a particular antibiotic is dependent on the patient’s weight along with the 
liver and renal status. Generally, possible regimes include combination of    
Penicillin G and an aminoglycoside (if renal function permits), as well as 
clindamycin (to cover streptococci, staphylococci, gram-negative bacilli, and 
anaerobes). Clindamycin is generally preferred over Penicillin G, as it’s efficacy is 
not affected by the inoculum size or stage of bacterial growth69. Broad-spectrum 
beta-lactam drugs such as Meropenem (Imipenem) cover Gram negative bacteria, 
especially Enterobactericeae like Escherichia coli. However, antibiotics are not as 
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efficient in case of NSTI as the infection is usually localized in deeper tissue layers 
and the blood supply to the site of infection is limited, thereby reducing the amount 
of antibiotics actively reaching the infection through translocation of antibiotics from 
blood.  
Along with the antibiotic treatment, urgent surgical procedures are important to 
improve the survival rate of the patient. Even a few hours delay in controlling the 
infection cause significant increases in mortality rates. Surgical removal of infected 
tissue is advantageous for survival as it reduces inflammation and restricts the 
spread of the local infection. Surgery also provides an increase of the local oxygen 
pressure in the infected area, thus boosting the activity of host immune cells. The 
debridement must be extensive, with adequate margins so that no infected tissue 
remains. Following initial debridement, the wound must be observed closely on a 
daily basis until the infection is controlled. In addition to administrating antibiotics 
and surgery, the patients undergo specialized treatments like hyperbaric Oxygen 
therapy (HBO) and Intravenous Immunoglobulin administration (IVIG) that 
increase the chances for better recovery. 
2.4.2 Hyperbaric Oxygen treatment (HBO) 
Hyperbaric oxygen treatment is given as an adjunctive therapy in diseases like 
necrotizing fasciitis so as to decrease the morbidity and mortality. In this treatment, 
the patient breathes 100% oxygen inside a chamber with an oxygen concentration of 
100% at a pressure of at least 1.4 atm. In regard to manage necrotizing fasciitis, 
numerous studies have been done that show a beneficial role of HBO treatment70. 
The region of infection is generally characterized by a low oxygen pressure and 
oxygen transportation is restricted due to reduced blood flow at the site. HBO 
treatment is seen to boost the host immune system for phagocytosis and eradication 
of the pathogen by increasing the oxygen pressure at the site of infection. The 
treatment includes initial therapy at 2.0 to 2.5 atm pressure given twice a day for 90 
min till the day no further extension of necrosis is seen and the infection is 
controlled. In addition to HBO, patients also need extensive care and administration 
of intravenous immunoglobulins (IVIG); especially when the causative organism is 
S. pyogenes71. 
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2.4.3 Intravenous Immunoglobulins (IVIG) as Adjunctive therapy 
Intravenous Immunoglobulins (IVIG) are a sterile preparation of concentrated 
antibodies from pooled plasma samples of at least 1000 healthy donors. Even though 
IVIG is dominated by IgG, there might be few traces of IgA found as well. Since a 
lack of protective antibodies is hypothesized to be one of the risk factors in the 
development of diseases like Streptococcal toxic shock syndrome (StrepTSS) and 
necrotizing fasciitis, IVIG could be one of the potential collateral therapies72. Since, 
IVIG is a pool of all antibodies derived from thousands of healthy donors; it is non-
specific and thus can cover various serotypes of S. pyogenes as well as the complete 
spectrum of superantigens and other streptococcal exotoxins. IVIG is also commonly 
used as a therapy for patients with immune deficiencies (hypogammaglobulinemia, 
X-linked agammaglobulinemia), low antibody titers, autoimmune diseases, and 
inflammatory diseases73.  
2.4.3.1 Mechanistic actions of IVIG in NF  
Several different mechanistic actions of IVIG have been described, that contribute to 
its positive effect during Streptococcal infections. These comprise modulation of 
cytokine responses, variation in immune cell function, interaction with idiotype-anti-
idiotypic network and antigen neutralization74. With respect to Superantigen (SAg) 
mediated diseases like StrepTSS, IVIG is seen to neutralize antigens (including 
SAgs), mediate bacterial opsonization, and modulate cytokine responses. IVIG 
contains antibodies that can opsonize the bacterial cells and hence lead to clearance 
by phagocytosis and subsequent killing75. Antibodies against streptococcal M-
proteins have also been found in IVIG preparations75 and analyses of plasma 
samples from patients pre- and post-IVIG treatment revealed a significant increase in 
anti-M-protein antibody titers75. Hence, bacterial opsonization and thence clearance 
is likely to be one of the mechanistic actions of IVIG, thus contributing to its 
effectiveness as an adjunctive therapy. Contrarily, when efficacy of IVIG was 
checked, in murine models of necrotizing fasciitis, no beneficial effect of IVIG was 
observed, thus failing to support the previous hypothesis76. However it could be 
anticipated that human antibodies were not efficient opsonins for murine 
phagocytes.   
IVIG also contains potent neutralising antibodies against streptococcal 
superantigens. These antibodies are able to inhibit the massive superantigen induced 
T-cell proliferation and cytokine releases under in-vitro conditions77. Even though 
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IVIG was able to neutralise all streptococcal SAgs, the degree of inhibition varied. 
However, only SpeA and SpeC have been studied extensively in this regard. Hence, 
IVIG can be considered as a ‘cocktail’ of different antibodies against various 
virulence factors of S. pyogenes. As already mentioned, IVIG is primarily composed 
of IgG, but can also have varying amounts of IgA and IgM. However, using 
polyspecific IgA and/or IgM preparations showed an inhibitory effect on the 
opsonizing and toxin-neutralizing capability of IVIG78. IgA and IgM were inhibiting 
superantigens, especially SpeA, where the most efficient neutralisation could be 
observed by a mixture containing all three immunoglobulins (IgG, IgA and IgM)78. 
Overall, optimization of IVIG therapy still remains to be proved in a clinical setting.  
2.4.3.2 Clinical studies of IVIG usage in NF 
There are many clinical cases wherein IVIG was used as an adjunctive therapy to 
treat Streptococcal infections, especially in StrepTSS79. Many case reports80,81,82, 
observational cohorts83, case-control study84 and multi-centered placebo-control 
study85 were conducted to study the efficacy of IVIG in clinical settings. StrepTSS is 
generally seen along with Necrotizing Fasciitis thence increasing the mortality even 
further higher.  
Recently, another clinical study called INSTINCT (Immunoglobulin for Necrotizing 
Soft Tissue Infection: a Randomized Control Trial) has been initiated by 
Rigshospitalet in Denmark that would estimate for the first time the effect of IVIG in 
a double blind study, taking 1:1 patients treated with IVIG and placebo                      
on outcome of patients with NSTI (https://www.clinicaltrials.gov/ct2/ 
show/study/NCT02111161). The study is currently in the process of patient 
recruitment (April 2014).   
The data of these studies suggests IVIG is beneficial as a collateral therapy and is 
effective against wide varieties of strains and serotypes80,81,82. It has been seen to 
neutralize superantigens, activate the complement system and facilitate the 
opsonization of S. pyogenes. Clinical studies including cohort studies and case-
control studies definitely substantiate the beneficial effects of administration of IVIG 
to patients of StrepTSS and necrotizing Fasciitis. Unfortunately, the efficacy of IVIG 
has only been reported in-vitro and there is nothing known about its efficiency in vivo 
with respect to the NSTI scenario. Additionally, IVIG is a cost-intensive therapy, 
usually accompanied by a wide variety of side effect like fever, increased blood 
pressure and in some cases, acute renal failure and hypersensitivity. There is, thus, a 
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need of development of more targeted and specific therapeutic treatments to rescue 
the NSTI patients.   
2.5 Aim of the study 
Necrotizing soft tissue infections (NSTI) including Necrotizing Fasciitis are rapidly 
progressing infections of the deeper layers of skin and subcutaneous tissue, 
spreading across the fascia. It requires intensive care with rigorous medication, 
ablative surgery and adjunctive therapies like hyperbaric oxygen therapy (HBO) and 
intravenous immunoglobulin administration (IVIG). IVIG is discussed to act by a 
variety of mechanisms like opsonization of the pathogen, activation of complement 
and neutralization of bacterial toxins. However, IVIG is a cost-intensive therapy, 
usually accompanied by a wide variety of side effect like fever, increased blood 
pressure and in some cases, acute renal failure and hypersensitivity. Considering the 
efficacy of IVIG treatment, we hypothesize that the lack of specific antibodies against 
the invading bacterial pathogen and/or against a certain combination of bacterial 
toxins could represent a risk factor for the development of a severe NSTI. This 
project also aids towards the development of more targeted alternatives to the 
common IVIG treatment. 
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3. Materials and Methods 
3.1 Materials 
3.1.1 Chemicals/ Solutions 
Table 3.1: Chemicals used in the study 
Chemical Supplier 
2-mercaptoethanol  Sigma 
2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) Roche 
6× loading dye (agarose gel electrophoresis) Thermo Scientific 
Acetic Acid Merck 
Acrylamid-Bisacrylamid (Rotiphorese Gel 30) Roth 
Agarose Broad Range (NEEO Ultra Quality) Roth 
Ammonium persulfate (APS)  Roth 
Ammonium Sulfate  J.T. Baker 
Ampicillin Applichem 
BactoTM Agar  Difco 
BactoTM Peptone  Difco 
BactoTMTryptone Difco 
BactoTM Yeast Extract  Difco 
Bovine serum albumin (BSA) Applichem 
Bradford reagent Bio-Rad 
Bromophenolblue Merck 
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Chemical Supplier 
Calcium chloride  Merck 
Chloroform Sigma Aldrich 
Citric acid Roth 
Columbia blood agar plates Becton Dickinson 
Coomassie Blue R-250  Serva 
Dipotassium hydrogen phosphate  Merck 
Disodium hydrogen phosphate  Merck 
Dimetheylsulfoxide (DMSO)  Applichem 
dNTP mix  Fermentas 
Dithiothreitol (DTT) Applichem 
Ethanol J. T. Baker 
Ethidium Bromide (EtBr) ICN-Biomedicals 
Ethylene diaminetetraacetic acid (EDTA) Applichem 
Fetal calf serum (FCS)  PAP 
Ficoll® PM400 Sigma 
Gene Ruler (1kB ladder) Fermentas 
Glycerol Fluka 
Glycine  Roth 
Glycogen  Roche 
High fidelity polymerase  Roche 
Hyaluronidase from Streptococcus pyogenes Sigma 
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Chemical Supplier 
Hydrochloric acid  Fluka 
Hydrogen peroxide  Applichem 
Imidazole  Applichem 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Applichem 
Kanamycin Roth 
Lysozyme  Sigma 
Magnesium Chloride  Merck 
Methanol  Baker 
Mutanolysin Fluka 
Mac (IdeS) “FabriCATORTM” Genovis 
Ni-NTA sepharose Qiagen 
Page Ruler™ Plus Pre-stained Protein Ladder  Thermo Fischer 
Ponceau S  Applichem 
Potassium di-hydrogen phosphate  Roth 
di- Potassium hydrogen phosphate  Roth 
Proteinase K  Fluka 
Protein G sepharose  Pharmacia 
RNase (DNase-free)  Applichem 
Restriction enzymes  NEB/Fermentas 
Skim milk  Difco 
SpeB “FabULOUSTM” Genovis 
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Chemical Supplier 
Sodium acetate   Merck 
Sodium carbonate  Merck 
Sodium chloride  Roth 
Sodium dihydrogenphosphate  Roth 
Sodium dodecylsulfate (SDS)  Roth 
Sodium hydroxide   Merck 
Streptolysin O (SLO) from Streptococcus pyogenes Sigma 
Sucrose  Fluka 
T4 DNA ligase New England Biolabs 
Taq-polymerase  Qiagen 
TEMED  Roth 
Todd-Hewitt Broth  Beckton Dickinson 
Tris (Trizma base)  Sigma 
Trypan Blue  Sigma 
Trypsin  Sigma 
Tryptic Soy Broth  Beckton Dickinson 
Trypsin-EDTA  PAN Biotech 
Triton X-100  Sigma 
Tween 20 Roth 
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3.1.2 Instruments 
Table 3.2: Instruments used in the study 
Instrument Company 
Agarose gel chambers  Horizon™ 58 
Autoclave-steam sterilizer  Biomedis 
Centrifuge 5417R  Eppendorf 
Centrifuge 5804R  Eppendorf 
CO2 water jacketed incubator  Forma Scientific 
Elisa plate reader Varioskan (ScanLab) 
French® pressure cell press (SLM Aminco, 40.000 PSI)  Thermo Fisher 
Gel docTM XR+ system BioLab 
Incubator  Kelvitron® Heraeus 
Infors HT multitron shaking incubator  Tuttnauer 
Leica MS 5 Microscope Leica Microsystems 
Microwave Pro 825  Sharp Electronics 
Nano Drop®  Thermo Scientific 
pH-meter 766  Calimatic Knick 
Power pack 200  BioRad 
Power pack 300  BioRad 
SONICS® VibraCell VC-50 
Sorvall® RC 6 Plus, rotor SLA-3000  Thermo Electron Corporation 
Sorvall® RC 6 Plus, rotor SS-34  Thermo Electron Corporation 
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Instrument Company 
Special accuracy weighing machine AE 260  Mettler 
SZ TrinocularStero Microscope Olympus 
Thermocycler Biometra 
ThermolyneVari-Mix Barnstead 
Transferpette® S-8 (multichannel pipet)  Biohit 
UV-transilluminatorHerolab UVT 2020 
Waterbath GFL 
Weighing machine PC 2000  Mettler 
Zeiss Microscope Axiovert 25 Zeiss 
3.1.3 Primers  
Table 3.3: Primers/Oligonucleotides used in the study 
Gene Name Primer Sequence (5’ to 3’) Reference 
Typing of streptococcal Isolates 
emmA TATTCGCTTAGAAAATTAA 
Facklam et al(1999)86 
emmB GCAAGTTCTTCAGCTTGTTT 
16s_FP AGAGTTTGATCCTGGCTC 
Zhou et al (1995)87 
16s_RP GGTTACTTGTTACGACTT 
Multiplex PCR 
speA_FP AAGAACC(A/T/G)AGAGATG(T/G)CAAC Friães et al (2013)88 
speA_RP ATAG(G/A)CTTTGGATACCATC(G/A)  
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Gene Name Primer Sequence (5’ to 3’) Reference 
speB_FP TTCTAGGATACTCTACCAGC 
Friães et al (2013)88 
speB_RP ATTTGAGCAGTTGCAGTAGC 
speC_FP CAGTCATACTGATTTCTACTATTTCACC 
speC_RP CAAGATAAATATCGAAATGACTAAAGTTC 
speF_FP CGAAATTAGAAAAGAGGAC 
speF_RP GGCTGAGCAAAAGTGTGTG 
speG_FP GTATCTTTAGGCATTACTGATC 
speG_RP GTTTACTATCTTTAGTAGCAAG 
speH_FP TTCAAGCAAATTCTTATAATACAACC 
speH_RP AAAGTCTCCATTGCCAAAATAATAC 
speI_FP TATGAGATGAGTAGTGTGGGAGTTATTAA 
speI_RP GTTCCTGAATCGTAACCTCTTTCTTATC 
speJ_FP CGAGAGCTATATTACAACAAAG 
speJ_RP CACTCCTTGTACTAGATGAGG 
speK_FP TATCGCTTGCTCTATACACTACTGAGAGT 
speK_RP CTTATCTTTAGCTGTTAATGTTCGTAATTC 
speL_FP GGACGCAAGTTATTATGGATGCTCA 
speL_RP TTAAATAAGTCAGCACCTTCCTCTTTCTC 
speM_FP TATCGCTTGCTCTATACACTACTGAGAGT 
speM_RP ATGAGTGAATAAATCGGTAAACTTTGTTG 
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Gene Name Primer Sequence (5’ to 3’) Reference 
ssa_FP GTGTAGAATTGAGGTAATTG 
Friães et al (2013)88 
ssa_RP TAATATAGCCTGTCTCGTAC 
smeZ_FP TAGAAGTAGATAATAATTCC 
smeZ_RP TTAGGAGT(C/T)AATTTCTATAT 
spd3_FP ATCGTCGTACTTGGCAAGGTT 
Borek et al (2011)89 
spd3_RP GCCGCTTCTTCAAACTCTTCG 
sdc_FP AAGCTTAGAAACTCTCTCGCCA 
sdc_RP AGTTCCAGTAATAGCGTTTTTCCGT 
sdaB_FP TATAGCGCATGCCGCCTTTT 
sdaB_RP TGATGGCGCAAGCAAGTACC 
sdaD_FP TTTACGCTGAATCGGGCACT 
sdaD_RP GGCTCTGGTTTGCTTTCCCA 
spyCEP_FP GATCCGGCCCATCAAAGCAT 
spyCEP_RP AGCTGCCACTGATGTTGGTG 
scpA_FP GCTCGGTTACCTCACTTGTCC 
scpA_RP CAATAGCAGCAAACAAGTCACC 
mac_FP TCTTGCCCTGTTGAAAGTGT 
mac_RP CGAGGTGGTATTTTTGACGCC 
sic_FP TTACGTTGCTGATGGTGTATATGGT 
sic_RP TTTGATAGAGGGTTTTCAGCTGGC 
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Gene Name Primer Sequence (5’ to 3’) Reference 
Cloning of Superantigens 
speA_FP CGCGGATCCCAACAAGACCCCGATCCAAG 
This study 
speA_RP CGGTCGACTTACTTGGTTGTTAGGTAGACTTC 
speC_FP CGCGGATCCGACTCTAAGAAAGACATTTCGAATG 
speC_RP CGGTCGACTTATTTTTCAAGATAAATATCGAAATGA 
speG_FP CGCGGATCCGATGAAAATTTAAAAGATTTAAAAAG 
speG_RP CGGTCGACCTAGTACGTTTTTAAGTAGATATC 
speH_FP CGCGGATCCAATTCTTATAATACAACCAATAGACA 
speH_RP CGGTCGACTTAGCTGATTGACACATCTACATG 
speI_FP CGCGGATCCATGAGTAGTGTGGGAGTTATTAATTTA 
speI_RP CGGTCGACTTATTTATTAAATTTAACTAAGTATATATC 
speJ_FP CGCGGATCCAGTGAAAATATTAAAGACGTTAAGC 
speJ_RP CGGTCGACTTATTTAGTCCAAAGGTAAATATCAAA 
speK_FP CGCGGATCCGATACGTACAATACAAATGATGTTAG 
speK_RP CGGTCGACCTAATCTTTAGAAAAATCTTCGTTTA 
speL_FP CGCGGATCCGAAGAGACTATTAATATTAAGGATATA 
speL_RP CGGTCGACTTAATTTTCTTTGTTTGTGAATAAATAG 
speM_FP CGCGGATCCGATGCTGTGTTGGTTAATAGCG 
speM_RP CGGTCGACCTAATTTTTAGAAAAATCTTCGTTTAAG 
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Gene Name Primer Sequence (5’ to 3’) Reference 
ssa_FP CGCGGATCCAGTAGTCAGCCTGACCCTACTC 
This study 
ssa_RP CGGTCGACTTATTTTTTGGTAAGGTGAACCTC 
smeZ_FP CGCGGATCCGAAGTAGATAATAATTCCCTTCTAAG 
smeZ_RP CGGTCGACTTAGGAGTCAATTTCTATATCTAAATG 
ska_FP GCGGATCCATTGCTGGATATGGGTGG 
ska_RP GCGTCGACTTATTTGTCTTTAGGGTTATC 
sic_FP CGCGGATCCAAACGTATACATCACGCAATTTTG 
sic_RP CGGTCGACTTACGTTGCTGATGGTGTATATG 
ska Sequencing 
Ska_FP ACCTTGCCGACCCAACCTGT 
McAurthur et al 
(2008)51 
Ska_RP GTGAACAGTTTCAAGTGACTGCGA 
3.1.4 Antibodies   
Table 3.4: Antibodies used in the study 
Antibody Type Dilution Company 
His Epitope-Tag (unconjugated) mAb IgG1 Primary 1:1000 Dianova 
Mouse HRP Anti-Human IgG Secondary 1:1000 BD PharmingenTM 
Privigen® Intravenous Immunoglobulins (IVIG) - 5mg/ml* CSL Behring 
Mouse Anti-SLO Antibody Secondary 1:1000 Antibodiy Online 
Mouse Anti-Hyaluronidase Antibody Secondary 1:1000 Abcam 
*Concentration of IVIG as in 100% Plasma; Diluted in 1x PBS  
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3.1.5 Kits 
Table 3.5: Kits used in the study 
Kits Company Catalogue Number 
QIAprep® Spin Miniprep Kit Qiagen 27104 
DNeasy Blood and Tissue Kit Qiagen 69581 
Nucleospin® Gel and PCR clean up kit Macherey-Nagel 740609.10 
SLIDEX Oxoid, Basingstoke, UK DR0585A 
PolymorphPrepTM Tebu-Bio 1114683 
3.1.6 Antibiotics 
Table 3.6: Antibiotics used in the study 
3.1.7 Buffers  
Buffers used in the study: 
 
1× PBS (pH 7.4) 
NaCl 137 mM 
KCl 2.7 mM 
Na2HPO4.2H2O 4.3 mM 
KH2PO4 1.47 mM 
  
 
Antibiotic Purpose Final Concentration 
Ampicillin Growing E. coli containing pQE30-TEV plasmid 100 µg/ml 
Kanamycin Growing E. coli strain M15   25 µg/ml 
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1× TBS (pH 7.4) 
Tris-HCl 50 mM 
NaCl 150 mM 
  
Tris/EDTA (TE) (10mM Tris/0.1mM EDTA) 
Tris (pH 7.5) 10 mM 
EDTA (pH 8.0) 0.1 mM 
  
1× TAE (pH 7.9) 
TrisHCl (pH 7.9) 40 mM 
Sodium Acetate (CH3COONa) 5 mM 
EDTA 1 mM 
  
Lysis Buffer (pH 8.0) 
NaH2PO4.H2O 50 mM 
NaCl 300 mM 
Imidazole 20 mM 
  
Elution Buffer (pH 8.0) 
NaH2PO4.H2O 50 mM 
NaCl 300 mM 
Imidazole 250 mM 
  
ACK Lysis Buffer   
NH4Cl 0.15M 
KHCO3 10mM 
EDTA 0.1mM 
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3.2 Bacterial Strains, Media and culture conditions 
3.2.1 S. pyogenes clinical isolates  
Table 3.7: Selected S. pyogenes INFECT cases used in the study 
Patient  Identified 
Pathogen 
Isolated from 
Treatment Collection center 
No. Age Gender Co-morbidities NSTI IVIG HBO 
2001 67 M None Yes S. pyogenes Tissue Yes Yes 
Rigshospitalet, 
Copenhagen 
2006 62 F Hypertension tractatae Yes S. pyogenes Blood Yes Yes 
Rigshospitalet, 
Copenhagen 
2015 70 F 
C.Pulm 2012 
Smoker 
Yes S. pyogenes Blood Yes Yes 
Rigshospitalet, 
Copenhagen 
2017 38 F None Yes S. pyogenes Tissue Yes Yes 
Rigshospitalet, 
Copenhagen 
3005 65 F 
Chronic obstructive  
lung Disease 
Hypertension 
Yes S. pyogenes N.A No No 
Karolinska  
University Hospital, 
Stockholm 
3012 42 F None Yes S. pyogenes N.A No Yes 
Karolinska  
University Hospital, 
Stockholm 
5003 79 M 
Malignancy colon 
Atrial fibrillation 
Chronic left leg edema 
Yes S. pyogenes Blood Yes Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
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5004 41 F None Yes S. pyogenes Wound Yes Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
5006 37 M None Yes S. pyogenes 
Wound elbow 
Yes No 
Sahlgrenska 
University Hospital 
Gothenburg 
Tissue right arm 
Wound right arm 
6013 34 F None Yes S. pyogenes 
Blood 
Neck 
Yes Yes 
University of Bergen 
Bergen 
6016 41 M None Yes S. pyogenes Elbow aspiration No No 
University of Bergen 
Bergen 
6018 39 F None Yes S. pyogenes Axilla No No 
University of Bergen 
Bergen 
6025 37 M Psoriasis Yes S. pyogenes Infected site No No 
University of Bergen 
Bergen 
6026 48 M None Yes S. pyogenes Infected site No No 
University of Bergen 
Bergen 
6028 41 M None No S. pyogenes Infected site No No 
University of Bergen 
Bergen 
6033 50 F None Yes S. pyogenes upper extremity No No 
University of Bergen 
Bergen 
6040 32 F None No S. pyogenes Upper Leg No No 
University of Bergen 
Bergen 
N.A: Not Available 
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3.2.2 Streptococcal Strains  
Table 3.8: Streptococcal strains used in the study 
Strain HZI Number emm type Reference 
S. pyogenes SF370 A302 M1 Ferretti et al (2001)90 
S. pyogenes  MGAS315 A570 M3 Beres et al (2002)91 
S. pyogenes  MGAS8232 A571 M18 Smoot et al (2002)92 
S. pyogenes  AP-1 A529 M1 Fiebig et al (2015)93 
S. gordonii DL1 GP202 - Oggioni et al (1996)94 
3.2.3 E. coli Strains 
Table 3.9: E. coli strains used in the study  
Strain Plasmid Gene Inserted Selection marker 
M15 [pREP4]§ - - Kan  
M15 [pREP4] pQE30-TEV - Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV speA Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV speC Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV speG Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV speH Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV speI Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV speJ Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV speK Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV speL Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV speM Amp (100µg/ml), Kan (25µg/ml) 
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Strain Plasmid Gene Inserted Selection marker 
M15 [pREP4] pQE30-TEV ssa Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV smeZ Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV sic Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV ska-1 Amp (100µg/ml), Kan (25µg/ml) 
M15 [pREP4] pQE30-TEV ska-2a# Amp (100µg/ml), Kan (25µg/ml) 
 
§
M15 [pREP4] cells were kindly provided by Guiseppe Gulotta but were initially bought from Quigen 
# ska-2a clone was kindly provided by Katharina Rox 
The M15 strains contained a repressory system (pREP4) that inhibited any leaky 
expression of the exotoxins. This repressory plasmid contained a Kanamycin cassette 
and therefore M15 cells were propagated under Kanamycin.  
3.2.4 Bacterial Cultivation 
3.2.4.1 Media 
All media used for bacterial cultivation was autoclaved prior to usage for 15 min at 
1210C and 15 psi above standard pressure. For growing bacteria on agar plates, 1.5% 
(w/v) agar was added to the required media before autoclaving. 
 
Table 3.10: Media used for bacterial cultivation 
Cultivation of Streptococcus pyogenes 
THY Media 
Todd Hewitt Broth  30 g/l 
Bacto™ Yeast Extract 5 g/l 
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Cultivation of Escherichia coli 
LB Media 
Bacto™ Tryptone 10 g/l 
NaCl 10 g/l 
Bacto™ Yeast Extract  5 g/l 
  
TSS Media 
Polyethylene glycol (PEG 8000) 12.5 mM 
Dimethyl Sulfoxide (DMSO) 700 mM 
MgCl2 20 mM 
3.2.4.2 Cultivation of bacteria 
Streptococcus pyogenes isolates were cultivated in THY-medium for 16 hours at 37°C 
without shaking. Bacteria were grown in sterile 50 ml falcon tubes with loose lids to 
allow air penetration. Working cultures were grown at 37°C until the desired optical 
cell density (ABS600nm= 0.5; approximately 108 cfu/ml) for all assays unless stated 
otherwise. For solid media cultivation, isolates were grown on THY agar plates. 
Bacteria were stored at —80°C in THY medium containing 25% glycerol for long term 
storage. 
E. coli strains were grown in LB Media containing appropriate antibiotics (Table 3.9). 
The strains were grown in conical flasks (with baffles) at 370C (or 300C after protein 
induction) with shaking at 150 rpm to increase aeration. Preparation of competent cells 
of M15 strain was performed using Transformation and Storage Solution (TSS) media. 
For long term storage, bacteria were stored at —80°C in LB medium containing 25% 
glycerol. 
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3.3 Molecular Biology Techniques 
3.3.1 DNA Isolation 
Bacterial genomic DNA was extracted from 15 ml THY overnight cultures. The cells 
were disrupted through Zirconia beads using a Fast Prep 24 device (MP Biomedical, 
USA) at 4 m/s for 30 sec. After removal of bacterial debris by centrifugation at 6000×g 
for 30 sec at room temperature, the DNeasy Blood and Tissue Kit (Qiagen, Germany) 
was used to extract the DNA from the lysate according to the manufacturer’s 
instruction. The quality of the isolated DNA was examined by 1% agarose gel 
electrophoresis (section 3.3.3). The concentration of DNA was estimated by Nanodrop 
(peQLab Biotechnologie, GmBH) and adjusted to 1 µg in 1×TE for further use. 
Extracted DNA was stored at —20°C. 
3.3.2 Plasmid Isolation 
Plasmid DNA from E. coli strains was isolated with QIAprep® Spin Miniprep kit 
according to the manufacturer’s protocol. Plasmid DNA was eluted in MilliQ and 
stored at —20°C until used. Isolated plasmid DNA was analyzed by agarose gel 
electrophoresis (section 3.3.3). 
3.3.3 Agarose Gel Electrophoresis  
The nucleic acid samples were analyzed by electrophoresis using 1% Agarose gels. 
Agarose gels were prepared by dissolving 1 g Agarose in 100 ml of 1×Tris-Acetate-
EDTA (TAE) buffer by heating to boil. When temperature reaches around 50°C, the 
Agarose solution was poured into a casting tray with combs. The gel was allowed to 
solidify for 30 min at room temperature, combs were removed and the gel was placed 
into an electrophoresis chamber and covered with 1×TAE. A commercial 1 kb nucleic-
acid size standard (Gene Ruler 1kb ladder, Fermentas) was added to estimate the 
molecular sizes of the nucleic acid samples. 5 µl of sample was mixed with 1 µl DNA 
loading dye and seperated for 1 hour at 90 Volt/cm. The gel was stained by immersing 
it in 0.5 µg/ml Ethidium Bromide (EtBr) solution for 10 min at room temperature with 
gentle agitation. Distilled water was used for destaining of the gels. The bands were 
visualized using an ultraviolet (UV) trans-illuminator.  
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3.3.4 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction (PCR), developed by Kary Mullis95, is a technique used to 
amplify a specific DNA fragment using repeated cycles of DNA melting, hybridization 
of specific primer molecules and DNA replication in vitro. This process is generally 
carried out by heat stable DNA polymerase (like Taq polymerase; enzyme isolated 
from Thermus aquaticus) in presence of deoxy-ribonucleotides (dNTPs) and sequence 
specific primers. PCR was used throughout this study to amplify specific genes during 
the screening processes, cloning and sequencing analysis. Appropriate positive 
(containing the gene of interest) and negative controls (MilliQ) were used to verify the 
accuracy of the results. 
3.3.4.1 Standard PCR 
Amplification of specific genes from bacterial genomic DNA was performed using 
Primers as listed in Table 3.3. The PCR mixture consisted of 3 µl of template DNA 
(approximately 1 µg), 1×PCR Buffer containing 15 mM MgCl2, dNTP-mix (10 mM per 
dNTP), 10 nmol of each primer, 1 unit of Taq DNA polymerase (Qiagen, Cat No. 
201203) filled with PCR grade water to a final volume of 25 µl. The standard reaction 
protocol has been listed below (Table 3.11) 
Table 3.11: Standard PCR Program 
Step Temperature Time 
Initial Denaturation 950C 5min 
Denaturation 950C 1 min 
Annealing T0C 1 min 
Extension 720C 1 min 
Final Extension 720C 10 min 
No. of cycles 27  
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emm typing: Amplification of emm genes was performed using emmA and emmB 
primers (Table 3.3). The PCR was performed in accordance to the standard protocol of 
the Center for Disease Control and Prevention, CDC (http://www.cdc.gov/streplab/m-
proteingene-typing.html). The PCR products were sequenced and emm type was 
allotted by strepBLAST (http://www2a.cdc.gov/ncidod/biotech/strepblast.asp). 
 
16S rRNA gene PCR: 16S rRNA gene from all bacterial isolates was amplified using 
primers 16s-FP and 16s-RP (Table 3.3). The annealing temperature used was 540C. A 
minimum of 1000 base pairs were covered. The PCR products were sequenced using 
Capillary Sequencing. NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used 
for bacterial species classification. 
ska sequencing PCR: Variable region from ska were amplified at 50°C annealing 
temperature. The PCR products were sequenced using Capillary Sequencing. All the 
sequences were trimmed using BioEdit and a dendogram was prepared by ClustalW96 
analysis.  
3.3.4.2 Multiplex PCR 
Bacterial genomes were tested for the presence or absence of 21 genes coding for 
streptococcal exotoxins using a multiplex PCR system that consisted of five 
independent reactions. The PCR was established based on previous protocols88,89 and 
was extended to the NSTI isolate collection. Primers are given in Table 3.3 whereas the 
controls used and the PCR conditions are given in Table 3.12 and Table 3.13 
respectively. For Reaction-1, 2 and 3, Go Green Taq® DNA polymerase (Promega, Cat. 
No. M3178) was used whereas for reaction 4 and 5, Recombinant Taq DNA Polymerase 
(Fermentas, Cat. No. EP0402) was used. Genomic DNA of already genome sequenced 
S. pyogenes strains (SF370, MGAS315 and MGAS8232) was used as positive controls 
whereas, genomic DNA of Streptococcus gordonii strain Challis GP204 was used as a 
negative control in all of the reactions. Since one strain did not carry all the exotoxins 
amplified in one reaction, a combination of two strains was sometimes used as control. 
 
 
 
 
 
Material and Methods 
 
47 
 
Table 3.12: Multiplex PCR  
Reaction Gene Size [bp] S. pyogenes Controls Reference 
1. 
speF 1,193 
Sf370 
MGAS315 
Friães et al (2013)88 
speJ 386 
speH 545 
ssa 706 
smeZ 628/629/616 
2. 
speA 202 
Sf370 
MGAS8232 
Friães et al (2013)88 
speB 300 
speI 411/412 
speL 460 
3. 
speC 660 
 
MGAS315 
MGAS8232 
Friães et al (2013)88 
speK 478/479 
speM 587 
speG 340 
4. 
sdc 600 
Sf370 
MGAS315 
Borek et al (2011)89 
sdaB 440 
sdaD 295 
spd3 784 
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Reaction Gene Size [bp] S. pyogenes Controls Reference 
5. 
sic 150 
Sf370 Borek et al (2011)89 
mac 389 
spyCEP 786 
scpA 622 
Table 3.13: PCR Program used in the Multiplex 
Steps 
Reactions 
1 2 3 4 5 
T t T t T t T t T T 
Initial Denaturation 95°C 05:00 95°C 05:00 95°C 05:00 95°C 03:00 95°C 03:00 
Denaturation 95°C 01:00 95°C 01:00 95°C 01:00 95°C 00:15 95°C 00:15 
Annealing 54°C 00:30 62°C 00:30 58°C 00:30 60°C 00:20 52°C 00:45 
Extension 72°C 01:30 72°C 01:30 72°C 01:30 72°C 02:00 72°C 02:00 
Final Extension 72°C 10:00 72°C 10:00 72°C 10:00 72°C 10:00 72°C 10:00 
No. of cycles 40 40 40 40 40 
t = time (in min); T = Temperature 
3.3.5 Preparation of Competent E. coli cells 
Competence is the ability of bacterial cells to take up extracellular DNA. Competence 
can be natural (genetic ability of bacteria under natural conditions) or artificial. 
Artificial competence arises by exposing the cells to divalent cations (like Mg2+ or Ca2+) 
in cold conditions that may change or weaken the cell surface structure, making it 
more permeable to DNA. The heat-shock (42°C for 90 sec) is thought to create a 
thermal imbalance on either side of the cell membrane, which forces the DNA to enter 
the cells through either cell pores or the damaged cell membrane. Competent cells 
were prepared for cloning of exotoxins in E. coli. E. coli M15 was grown in TSS media 
supplemented with 25 µg/ml kanamycin (Table 3.10) till mid-exponential phase 
(ABS600nm = 0.4) at 37°C with shaking at 150 rpm for sufficient aeration. The flask was 
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incubated on ice for 10 min and then centrifuged at 4000×g for 10 min at 4°C. The pellet 
was resuspended in 20ml fresh TSS media. 100µl aliquots were prepared in 1.5ml 
micro-centrifuge tubes and shock-frozen in liquid nitrogen. The aliquots were stored at 
—80°C until further used. 
3.3.6 Molecular Cloning  
Molecular cloning is a technique to recombinantly express and purify a specific protein 
in a different background than the cell originally producing it. To identify antibodies 
against streptococcal exotoxins in NSTI patient plasma samples, a set of selected 
streptococcal exotoxins (n=14) along with the empty vector (background control) were 
cloned, over expressed and purified according to the outline mentioned below. 
 
Figure 3.1: Outline of the cloning protocol. The vector (bacterial plasmid) and insert (gene of interest) are cut with 
restriction enzymes (1) to generate sticky ends. Ligation (2) of the sticky ends produces the recombinant plasmid. 
This plasmid is then transformed (3) in E. coli cells. Cell division (4) results in many identical copies of bacterial cells, 
all carrying the recombinant plasmid. 
Bacterial 
Plasmid
Gene of Interest
Amplified DNA
Recombinant 
Plasmid
1
2
3
4
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Step-1: PCR Amplification of the Insert 
The gene of interest was amplified using standard PCR program (section 3.3.4.1). The 
size of the PCR product was confirmed by agarose-gel electrophoresis. The primers, 
product size and PCR program for cloning of superantigens are listed in Table 3.3. For 
removal of unused dNTPs and primers, PCR products were purified using 
Nucleospin® Gel and PCR clean up kit from Macherey-Nagel following manufacturer’s 
instruction. 
 
Figure 3.2: Map of the vector pQE-30 TEV. The vector pQE30 is modified to introduce a 6×His Tag cleavage site 
named as TEV
97
. The vector contains an Ampicillin resistance cassette. PT5 stands for Promotor region; lac O is lac 
operon site (that is inducible by IPTG); RBS is the Ribosome binding site and MCS is a multiple cloning site. ATG 
demarcates the start codon (Methionine). ColE1 is the site of origin of replication. 
Step-2: Restriction Digestion 
The restriction enzymes BamHI and SalI were selected to digest insert and vector 
pQE30-TEV in order to produce ‘sticky ends’ for ligation. The reaction mix consisted of 
10 µl (around 1 µg) of template DNA, 1×BamHI-SalI buffer, 2 µl of each restriction 
enzyme filled with water to 35 µl. The restriction mix was incubated at 37°C for 1 h. 
The digested fragments were purified using Nucleospin® Gel and PCR clean up kit 
from Macherey-Nagel. A 1% agarose gel was used to check the digestion using uncut 
vector and vector cut with only BamHI and SalI as controls.  
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Step-3: Ligation and Transformation 
The double digested vector and the insert were mixed in a ratio of 1:4 along with         
1× T4 Ligase buffer and 1 µl of T4 Ligase to obtain a final volume of 11.5 µl. The 
mixture was incubated for 16 h at 16°C to allow the generation of the recombinant 
plasmid by ligation of generated ‘sticky ends’. The ligated product (Recombinant 
plasmid) was added to 100 µl of prepared M15 competent cells (Section 3.3.5). The cells 
were incubated on ice for 30 min. Subsequently a heat shock at 420C for 90 seconds was 
applied and 700 µL of fresh LB broth was added. This culture was incubated at 370C for 
shaking for 1 h. Afterwards, it was centrifuged at 7500×g for 3 min at room 
temperature. 750 µL of the supernatant was discarded and the bacteria were spread on 
LA-Amp-Kan plate (Transformation Plate) and incubated for 16 h at 370C. 
Step-4: Identifying positive Clones 
The colonies from the transformation plate were transferred to a fresh LA-Amp-Kan 
plate (Master Plate) for further processing. The selection of positive clones was 
performed by Colony PCR. Therefore a single colony was picked from the antibiotic 
selection plate and dissolved in 30 µl autoclaved MilliQ. The sample was incubated at 
95°C for 15 min to lyse the cells. 10 µl of this sample was used as a template for PCR. 
PCR was performed by the protocol mentioned below (Table 3.15) using the standard 
PCR program (Table 3.10)  
Table 3.14: PCR Program used for Colony PCR 
5× Taq Buffer containing MgCl2  5 µl 
10 mM dNTPs 0.6 µl 
10 nmol Forward Primer 0.6 µl 
10 nmol Reverse Primer 0.6 µl 
5U/µl Taq Polymerase 0.2 µl 
1 µg Template 10 µl 
dH2O Up to 25 µl  
The positive clones were picked from the master plate and were inoculated in 5 ml LB 
media containing Ampicillin (100 µg/ml) and Kanamycin (25 µg/ml). The plasmid was 
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isolated as mentioned in Section 3.3.2. The plasmids were analyzed by sequencing 
(Capillary Sequencing). Positive clones with the 100% similarity to the gene of interest 
were stored in a cryo-stock containing 25% glycerol at —80°C. 
Step-5: Protein Over-expression and Purification 
Since the applied cloning strategy allowed attaching a His-tag to the proteins of 
interest, their purification was done by Affinity Chromatography. Briefly, the 
constructed E. coli clones carrying the exotoxin genes within the pQE30-TEV vector 
were inoculated in 500 ml LB media containing Ampicillin (100 µg/ml) and Kanamycin 
(25 µg/ml) for 3 h at 37°C with shaking at 150 rpm for sufficient aeration. The proteins 
were induced for 16 h at 30°C with 1mM IPTG at mid-log phase (ABS600nm = 0.4). For 
SpeG, the induction time was reduced to 4 h as a longer incubation time induced an 
insolubility of the over-expressed protein. Afterwards the bacterial cells were pelleted 
by centrifuging at 6000×g for 10 min at 4°C and resuspended in 10ml of Lysis Buffer 
(Table 3.7). The cells were lysed thrice by French® pressure cell press (18,000 psi) and 
centrifuged at 11000×g for 15 min at 4°C. The supernatant was loaded onto Ni-NTA 
columns to allow binding of the protein via the His-tag to the column matrix. The 
column was washed thrice with 5 ml of 20mM Imidazole (Washing Buffer same as 
Lysis Buffer, Table 3.7) and the protein was eluted by 3 ml of 200 mM Imidazole 
(Elution Buffer; Table 3.7). The eluted protein was dialyzed using a 3 kDa cut off 
membrane at 4°C for 16 h for buffer exchange with PBS.   
3.4 Biochemical Techniques 
3.4.1 Discontinuous Sodium dodecyl sulfate Polyacrylamide Gel Electrophoresis 
(DISC SDS-PAGE) 
SDS-Polyacrylamide Gel Electrophoresis (PAGE) is a method to separate proteins 
based on their molecular size. Sodium dodecyl sulfate (SDS) is an anionic detergent. 
Binding of SDS imparts uniform charge per unit mass to the proteins thus rendering 
the separation solely on the basis of molecular mass. Addition of β-mercaptoethanol or 
dithiotretol (DTT) further denatures all di-sulphide bonds present within a protein. 
Thus, due to the negative charge of SDS, proteins migrate towards the anode (the 
positive electrode) and are separated based on their molecular weight and independent 
of their charge. Large proteins are retained within the gel matrix and migrate slower 
than smaller proteins with lower molecular mass. DISC-PAGE is used in this study as 
pH values within the gel vary to change the average charge of the counter ions during 
the run to improve resolution. Proteins are first concentrated in a low percentage 
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stacking gel (5% acrylamide) with a pH of 6.8 and then they migrate into a higher 
percentage resolving gel (10% acrylamide) with a pH of 8.8 in which they are separated 
according to their size. Approximately, 5 ml of resolving gel (10% acrylamide) and 2 ml 
of stacking gel (5% acrylamide) were prepared for electrophoresis. For SDS-PAGE 
analysis, the protein samples were mixed with sample loading buffer in a ratio of 5:1 
and kept at 94°C for 5-10 min. The samples were loaded on the SDS gel and separated 
using Mini-Protean3 cell (BioRad) by applying 30 mA (constant current). A 
PageRulerTM Prestained Protein Ladder (10 to 250 kDa, Thermo Fischer) was loaded as 
a standard for molecular mass. Following electrophoresis, the gel was either stained 
with Coomassie Brilliant Blue R-250 (Section 3.4.1.1) or used for western blot analysis 
as described in section 3.4.2. 
SDS Loading Buffer  
 0.2 M Tris-Cl (pH 6.8) 
 0.02% β -Mercaptoethanol 
 3 % SDS 
 30 % Glycerol 
 0.2 % Bromphenolblue 
Resolving Gel  
 10 % Acrylamide/Bisacrylamide (30:0.8) 
 0.37 M Tris/HCl (pH 8.8) 
 0.1 % SDS 
 0.5 μl/ml TEMED 
 0.5 mg/ml APS 
Stacking Gel  
 5 % Acrylamide/Bisacrylamide (30:0.8) 
 0.125 M TrisHCl pH 8.8 
 0.1 % SDS 
 0.5 μl/ml TEMED 
 0.5 mg/ml Ammonium peroxodisulfate (APS) 
5X Running buffer  
 25 mM Tris 
 192 mM Glycine 
 0.1% SDS 
3.4.1.1 Coomassie Staining 
To visualize proteins on an SDS-PAGE gel, the gel was stained for 3 h in Coomassie 
Brilliant Blue R-250 staining solution. The gel was washed with dH2O and incubated in 
destaining solution for 2 h. Gels were scanned using a HP DeskScan II 6100C/T and 
analyzed using GIMP 2.6.1. 
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Coomassie stain solution  
 0.25 % (v/v) Coomassie Brilliant Blue R-250 
 50 % (v/v) Methanol 
 10 % (v/v) Acetic acid 
 Added to distilled water 
Destaining Solution  
 20 % (v/v) Methanol 
 7 % (v/v) Acetic acid 
 Added to distilled water 
 
3.4.2 Immuno-Western Blot Analysis 
For specific detection of individual proteins, immune-western blot analysis was 
performed. Proteins were separated by SDS-PAGE and electro-transferred to a 
nitrocellulose membrane (BioRad) in transfer buffer at 100 V for 1 h at 4°C using a 
MiniTrans-Blot cell (BioRad). The protein transfer was confirmed by staining the 
nitrocellulose membrane with Ponceau S as described in section 3.4.2.1. After washing 
thrice with 25 ml TBST (TBS in 0.05% Tween 20), the membrane was incubated for 2 h 
with 25 ml of blocking buffer (5% skim milk dissolved in TBST) at room temperature to 
block non-specific binding sites on the membrane. Subsequently the membrane was 
incubated for 16 h at 4°C with 5 ml primary antibody, diluted 1:1000 in TBST 
containing 5% skim milk. Afterwards the membrane was washed twice with 20 ml 
TBST and incubated with 5 ml HRP conjugated secondary antibody (diluted 1:1000 in 
TBST containing 5% skim milk) for 1 h at room temperature. The blot was washed 
three times with 20 ml TBST for 10 min each and immune-reactive proteins were 
detected by X-ray films using ECL Western Blotting Detection Kit according to the 
manufacturer’s instruction (Amersham). 
 
 
Transfer Buffer  
 50 mM Tris-Base 
 40 mM Glycine 
 20 % Methanol (v/v) 
  
Blocking Buffer  
 5 % (w/v) Skim milk  
 Dissolved in TBST 
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3.4.2.1 Ponceau Staining 
To verify the protein transfer efficiency and immobilize the proteins on the 
nitrocellulose, the membrane was stained with 20 ml Ponceau S stain for 5 min. 
Ponceau S is a sodium salt of a diazo dye of light red color. The staining of the 
membrane with Ponceau S allows the reversible staining of proteins on a nitrocellulose 
membrane by ionic interactions. The membrane was rinsed with 20 ml TBST until the 
signals disappeared and probed for western blot analysis as described in section 3.4.2. 
 
Ponceau stain solution  
 0.2 % (v/v) Ponceau S 
 3 % (v/v) Trichloroacetic acid 
 3 % (v/v) Sulfosalicylic acid 
3.4.3 Estimation of Protein Concentrations 
The concentration of purified proteins was determined by Bradford Assay98. Briefly,      
40 µl of Bradford solution (BioRad) was added to 10 µl of a protein solution in a 
microtiter plate; double distilled water was added to a total volume of 200 µl. The 
absorption at 595 nm was measured using an ELISA-Reader (Tecan Sunrise) without 
any prior incubation. The standard curve was plotted by generating a serial dilution 
standard curve using BSA. The absorbance of known concentrations of BSA was 
measured at 595 nm and the amount of protein in the solution was estimated by 
comparison with the standard.  
3.4.4 IgG Depletion 
To analyze the role of IgG mediated immunity during the development of NSTI, a pool 
of commercially available human plasma was depleted of IgG to serve as negative 
control for further experiments. For this, pooled human Li-Heparin Plasma (Innovative 
Research Inc.) was centrifuged at 14,000×g for 10 min at room temperature prior use to 
remove freezing induced precipitates of fibrinogen which may hinder the depletion 
process. The removal of the IgG content was performed using Sepharose Protein G 
beads (GE Healthcare). 1 ml of the resin was mixed with 2 ml of plasma and incubated 
at room temperature for 1 hour with continuous gentle agitation. The supernatant was 
collected, the beads were washed with 5 ml PBS and IgG was eluted using 2 ml of 0.2 
M glycin. The efficiency of depletion was checked by western blotting as described in 
section 3.4.3 
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3.5 Immunological Techniques 
3.5.1 Typing for Surface Antigen 
Streptococcal isolates were streaked on a Blood Agar Plate (Columbia Blood Agar with 
5% Sheep Blood, Thermo Scientific) and kept for 16 h at 37°C. A single colony was 
picked to determine the surface antigen type using a commercial SLIDEX kit (Oxoid, 
Basingstoke, UK) according to manufacturer’s instruction. 
3.5.2 Enzyme Linked Immunosorbent Assay (ELISA) 
ELISA is a common laboratory technique that can be used to measure the concentration 
of an analyte in solution by using enzyme immunoassays. ELISA is a multi-step 
process that involves at least one antibody with specificity for a particular antigen. The 
protein (either an antigen or an antibody) is immobilized by adsorption to a 
polystyrene 96 well plate. Coating is followed by blocking wherein all the unoccupied 
surfaces in the well are captured by either BSA or skim milk. The detection antibody is 
added, forming a complex with the antigen. The detection antibody can be covalently 
linked to an enzyme, or can itself be detected by a secondary antibody that is linked to 
an enzyme through bioconjugation. Between each step, the plate is washed with a 
mild detergent solution to remove any proteins or antibodies that are non-specifically 
bound. After a final washing step, the plate is developed by adding an 
enzymatic substrate to produce a visible signal, which indicates the quantity of antigen 
in the sample. The established ELISA protocol is listed in Table 3.15. 
Table 3.15: Established ELISA protocol 
STEP PROTOCOL 
Coating 50 µl of 3 µg/ml protein in TBS was added per well and incubated 
for 16 h at 4°C 
Washing Each well was washed three times with 300 µl TBST 
Blocking 250 µl 5% BSA in TBS was added to each well and incubated at 
37°C for 1 hour 
Washing Each well was washed three times with 300 µl TBST 
Primary Antibody 50 µl of each plasma sample (1:50 dilution plasma in TBS with 
5%BSA) was added and incubated overnight at 4°C 
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Washing Each well was washed three times with 300 µl TBST 
Secondary Antibody 50 µl of secondary antibody in TBS (1:1000 dilution) with 5% 
BSA was added to each well and incubated at 37°C for 1 hour 
Washing Each well was washed three times with 300 µl TBST 
Developing 200µl ABTS (800 µg/ml with 0.1% H2O2) was added to each well 
and incubated for 30 min at 37°C 
Detection The Absorption at 416nm was determined using a suitable 
plate reader (Varioscan, ScanLab) 
For one serum sample, antibody titers against all selected exotoxins were tested in two 
seperate plates: one for superantigens and other for the second set of exotoxins. The 
plate layout is displayed in Figure 3.3. Empty vector purification was diluted in the 
same ratio as the corresponding superantigen and served as the ‘background’ control. 
The amount of coated toxin was verified by the use of an Anti-His antibody that served 
as the ‘Toxin coating control’. The obtained absorbance values of antibodies in INFECT 
patient plasma against toxins and empty vector purification were normalized within 
different days using the absorbance values obtained from the ‘Toxin coating control’. 
For statistical significance analysis, ANOVA test was applied between absorbance 
values obtained from toxins and empty vector purification (p<0.05, n=3). 
Out of the four commercially available exotoxins (SpeB, Mac, SLO and Hyl), SpeB and 
Mac were His-tagged and hence an Anti-His antibody was used to generate ‘Toxin 
coating control’ as in described for the purified superantigens. An Anti-SLO and Hyl 
antibodies were used to control the coating efficiency.  
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Figure 3.3: ELISA plate layout. Each column of the 96 well plates was coated with a different toxin. Same dilutions 
of the empty vector purified proteins were coated (row D-F) for each toxin to serve as the ‘Background titer test’. For 
primary antibodies, row A-F was incubated with INFECT patient plasma whereas row G-H was incubated with Anti-
His antibody for checking the efficiency of the coating. The obtained absorbance values were normalized against the 
absorbance values of ‘Toxin coating test’ and statistical significance test was done by applying ANOVA between 
normalized values of ‘Anti-toxin titer test’ and ‘Background titer test’.  
3.5.3 T-cell Proliferation Blocking Assay  
A T-cell proliferation Assay was established to determine the protectivity of detected 
antibodies within the patient plasma samples against superantigens. Lymphocytes 
were isolated from Buffy coat, a fraction of anti-coagulated blood that contains 
leukocytes and platelets. The buffy coats were collected in accordance with rules of the 
Regional Ethics Committee of Lower Saxony, Germany and the declaration of Helsinki. 
Buffy coats from blood donations of healthy human volunteers who provided 
informed consent were obtained from the Institute for Clinical Transfusion Medicine, 
Klinikum Braunschweig, Germany. Buffy Coats were produced from whole blood 
donations on day 1 by using the Top & Bottom Extraction Bag System (Polymed 
Medical DevicesTM, Triple Blood Bag System, No. 7300; containing CPDA-1. 20 ml 
Ficoll Reagent (GE life Sciences) was poured in two separate falcon tubes and 30ml 
buffy coat were carefully layered on the top of the Ficoll fraction. The tubes were 
centrifuged for 20 min at 450×g at room temperature.   
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Figure 3.4: Ficoll gradient. Buffy coat was carefully layered on top of Ficoll regent and centrifuged at 450×g for    
30 min at 19°C. Different fractions of blood are separated based on their densities and have been labelled beside 
the tube. 
The gradient is formed as depicted in Figure 3.4. The cell layer containing 
lymphocytes, monocytes and platelets was transferred to a new Falcon tube containing 
50 ml 1×PBS. The cells were washed at 400×g for 10 min. The supernatant was 
discarded carefully and the washing step was repeated two times. Erythrocyte 
contaminations in the lymphocyte fraction were removed by ACK buffer lyses (10ml, 
37°C for 10 min) (section 3.1.7). The cells were washed two times with 50 ml PBS at 
400×g for 6 min to remove erythrocyte cell debris. The purified lymphocytes were 
resuspended in RPMI containing 10% FCS and counted using Neubauer Cell Counter 
under Axiovert 25 microscope (Zeiss) after staining with Trypan Blue. The cell density 
of purified cells was adjusted to 2×106 cells/ml, 100 µl aliquoted in 96 well plate 
according to the plate layout described in Figure 3.5. 
In a 96 well cell culture plate, a concentration gradient of superantigen was prepared in 
RPMI to determine the optimal concentration with maximum T-cell proliferation. To 
analyze protection potential of antibodies against the unspecific stimulation of T-cell 
proliferation of purified superantigens, 20% plasma (Day 0 and 3) diluted in PBS was 
incubated together with different superantigen concentrations and incubated at 37°C 
for 1 hour. 100µl of 2×106 cells/ml of isolated T-cells were subsequently added to the 
well and the plate was incubated at 37°C with 5% CO2 for 6 days for T-cell activation 
and proliferation. IgG depleted plasma and IVIG served as the negative and positive 
control respectively. 
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Figure 3.5: Plate Layout for T-Cell Proliferation Assay. Each column of the 96 well plates was tested with a 
different toxin. Defined concentrations of superantigens were incubated with 20% INFECT plasma (Day 0 plasma in 
row A-B and Day 3 plasma in row C-D) diluted in PBS and were kept at 37°C for1 h. Superantigens incubated with 
IVIG (row E-F) and IgG depleted plasma (row G-H) served as positive and negative controls. 100µl of 2×10
6
 cells/ml 
of isolated T-cells were subsequently added to the well and the plate was incubated at 37°C with 5% CO2 for 6 days 
for T-cell activation and proliferation. The inhibition efficiency was calculated by taking T-cell proliferation in 
untreated (negative control) as 100%, as mentioned in the figure.  
For detecting the extent of T-cell proliferation, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was added to the wells to reach a final concentration of 
1 mg/ml. MTT is a yellow tetrazole that is converted to purple formazan in living cells 
by NAD(P)H-dependent cellular oxidoreductase enzymes. The cells were further 
incubated for 3 hours at 37°C with 5% CO2, and afterwards centrifuged at 3000×g for  
10 min at 19°C. The supernatant was carefully removed and 100µl DMSO was added to 
dissolve the formazan crystals into a colored solution. The cells were incubated for     
15 min at room temperature and the absorbance of the colored solution was measured 
at 560 nm with reference wavelength of 670 nm.  
For statistical significance analysis, Student t-Test was applied between absorbance 
values obtained from determining proliferation by superantigens incubated in INFECT 
patients plasma or IgG depleted plasma (p<0.05, n=3). Percentage inhibition was 
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calculated by considering proliferation of T-cells by superantigens incubated in IgG 
depleted plasma as 100%.  
3.5.4 Opsonophagocytosis Assay 
To investigate if the antibodies against the bacteria itself would mediate efficient 
opsonization and subsequent killing, opsono-phagocytosis assay was established. 
Blood was always taken freshly from right median cubital vein of healthy mid-aged 
volunteers (Ethical Approval Number BO/07/2013) using Sodium Heparin Vacutainer® 
and Safety-LokTMsystem (BD Biosciences). Streptococcus pyogenes was grown as 
described in section 3.2.4.2 until mid-logarithmic growth phase (ABS600nm = 0.4), washed 
twice with sterile PBS at 2000×g for 3 min and adjusted to ABS600nm = 0.5 (~5 x108 cfu/ml) 
in PBS. 108 bacterial cells of a selected INFECT isolate were added to 1 ml of the 
corresponding INFECT plasma sample (20% in 1×PBS) and incubated at 37°C for         
30 min with gentle agitation on test tube rocker (Thermo Scientific Vari Mix). Bacterial 
cells incubated in IgG depleted plasma with and without 20% IVIG diluted in PBS 
served as the positive and negative control respectively. Thereafter, the bacterial cells 
were washed twice with sterile PBS and diluted to 2×106 cfu/ml in RPMI with 10% FCS. 
To analyze if the patient antibodies mediate efficient opsonization of bacterial cells, in-
vitro phagocytosis assays were performed99. Human neutrophil granulocytes were 
isolated from fresh human blood using PolyMorphPrepTM system (Axis-Shield) 
following the manufacturer’s instruction. The purified cells were resuspended in RPMI 
(with 10% FCS) and adjusted to 2×106 cells/ml by trypan blue dye exclusion method 
using an Improved Neubauer chamber and Axiovert 25 microscope (Zeiss). 1 ml of 
RPMI (with or without isolated neutrophils) was infected with 2×106 cfu/ml of bacteria 
(MOI=1) for 3 h and incubated slowly rolling in an Hybridization Oven (Model 1012, 
Shel Lab) at 37°C and 6 rpm. At hourly intervals, 50 µl aliquots were taken and added 
to 450 µl sterile PBS. 5 sec low power ultrasonic treatment (LabSonic U) was performed 
to disrupt bacterial aggregates as well as blood cells and samples were analyzed for 
remaining bacterial cell density on ten-fold serial dilution series in sterile PBS. 
Triplicates of 10 µl of each dilution were spotted on THY Agar plate and kept at 37°C 
for 16 h. The colonies were counted using the SZ TrinocularStero Microscope 
(Olympus) and cfu/ml was calculated.  
                 
 
Results 
 
62 
 
4. Results 
The human immune system constitutes the major line of defense against invading 
bacterial pathogens. During an infection event, the adaptive immune system is able to 
boost the innate immune response by specific antibodies that lead to complement-
mediated opsonization of bacterial cells via the classical pathway to increase 
recognition and phagocytic clearance as well as neutralizing secreted bacterial toxins. 
Consequently the lack of specific antibodies against the invading bacterial pathogen 
and/or against a certain combination of bacterial toxins could represent a risk factor for 
the development of a severe NSTI. 
4.1 Characterization of Bacterial Isolates 
4.1.1 Selection and Typing of Isolates 
To investigate the role of the serological background within the NSTI scenario, cases of 
Necrotizing Fasciitis were recruited and the corresponding bacterial isolates were 
collected in Rigshospitalet (Copenhagen), Karolinska University Hospital (Stockholm), 
Sahlgrenska University Hospital (Gothenburg) and University of Bergen (Bergen) 
under the European Union funded project named INFECT (http://www.fp7infect.eu/). 
Additionally control cases were enrolled wherein patients had suffered from severe 
skin and tissue infections that did not develop a necrotic stage. The bacterial isolates 
were obtained either by swabbing from the site of infection or through blood collected 
from infected patients. A total of 163 INFECT cases were collected over the period of 
two years (2013-2015), wherein, 59 cases were identified to be caused by members of 
the genus Streptococcus. To validate the bacterial species of the collected isolates, 16s 
rDNA sequence comparison was performed. INFECT Isolates identified as members of 
the genus Streptococcus were further analyzed by specialized typing methods like 
hemolysis screening and surface antigen (SLIDEX) determination. Furthermore, all 
streptococcal cases were characterized based on their M-protein. The M-protein is a 
surface bound virulence related protein that was first used in 1946 for characterizing 
and typing various S. pyogenes isolates100. Later, homologues of the M-protein were also 
found in Streptococcus dysgalactiae subsp. equisimilis (SDSE) isolates101. PCR 
amplification and sequence database driven comparisons of sequences of various emm 
genes enabled assigning different M-types to the isolates (emm typing) (Figure 4.1). 
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Figure 4.1: Agarose gel picture of PCR amplified emm and 16s rDNA genes from genomic DNA of NSTI 
isolate 2001 for sequencing. The emm gene and 16s rRNA gene were amplified from the genomic DNA of 
INFECT isolates for capillary sequencing. The PCR products were analyzed on 1% agarose gel, stained with 
Ethidium Bromide. The separation of DNA was based on the length/size of the PCR product. Size of the bands was 
estimated by comparison with standard 1 kb GeneRuler. 
All generated typing results were compiled into a database, which enabled a 
comprehensive overview about the species and emm-type distribution of all 
streptococcal NSTI and non NSTI control cases enrolled within the collection time of 
two years and constitutes the starting point for the selection process towards further 
serological analyses (Table 4.1.1). 
Table 4.1.1: Typing results of streptococcal INFECT Isolates 
Number Hemolysis Slidex 16s rDNA sequencing M-type 
2001 beta A S. pyogenes M1 
2006 beta A S. pyogenes M1 
2015 beta A S. pyogenes M87 
2017 beta A S. pyogenes M28 
2028 beta A S. pyogenes M3 
3005 beta A S. pyogenes M89 
3012 beta A S. pyogenes M77 
5003 beta A S. pyogenes M77 
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Number Hemolysis Slidex 16s rDNA sequencing M-type 
5004 beta A S. pyogenes M28 
5005 beta G S. dysgalactiae ssp. equisimilis stG485.0 
5006 beta A S. pyogenes M1 
5006 beta A S. pyogenes M1 
5006 beta A S. pyogenes M1 
6003 beta A S. pyogenes M1 
6003 alpha C S. anginosus - 
6004 beta A S. pyogenes M3 
6006 beta C S. dysgalactiae ssp. equisimilis stG62647 
6007 beta G S. dysgalactiae ssp. equisimilis stG2078.0 
6008 alpha - S. constellatus - 
6009 alpha - S. anginosus - 
6012 beta F S. dysgalactiae ssp. equisimilis stG62647 
6012 alpha - S. oralis - 
6013 beta A S. pyogenes M1 
6013 beta A S. pyogenes M1 
6016 beta A S. pyogenes M1 
6017 beta G S. dysgalactiae ssp. equisimilis stG643.0 
6017 beta G S. dysgalactiae ssp. equisimilis stG643.0 
6018 beta A S. pyogenes M1 
6020 beta C S. dysgalactiae ssp. equisimilis stG62647 
6025 beta A S. pyogenes M1 
6026 beta A S. pyogenes M4 
6028 beta A S. pyogenes M4 
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Number Hemolysis Slidex 16s rDNA sequencing M-type 
6033 beta A S. pyogenes M63 
6040 beta A S. pyogenes M28 
From the applied typing of the INFECT isolates, it was found that all S. pyogenes 
isolates showed a β hemolytic phenotype, while growing on blood agar and expressing 
the ‘A’ antigen whereas SDSE isolates expressed either ‘C’ or ‘G’ surface antigen. 
Furthermore, all the S. anginosus isolates were α- hemolytic with no typical surface 
antigen.  
On the basis of initial microbiological culturing and typing, the distribution of all 
species within the INFECT case collection (Appendix 6.2) was examined to determine 
occurrences of various causative pathogens of NSTI and frequencies of streptococcal 
infections (Figure 4.2). 
 
 
Figure 4.2: Pie-chart depicting the distribution of different NSTI types, causative bacterial species and 
streptococcal M-types of the NSTI case collection within two years (2013-2015). (A) Distribution of different 
types of NSTI cases collected under the project INFECT. Type I refers to poly-microbial infections, Type II are 
infections caused by S. pyogenes whereas clostridial species causing NSTI is assigned as Type III. Microbiological 
culturing was done from the infected site or from withdrawn blood of the patient. Each type is assigned to a particular 
case based on the causative organism. (B) Distribution of various species of the genus Streptococcus in the NSTI 
isolates collection. The 16s rRNA gene was amplified, sequenced and thereafter compared with existing databases 
to assign a particular species to the NSTI isolate collection. (C) Distribution of different M-types in the collected S. 
pyogenes isolates. The emm gene was amplified and sequenced to compare with CDC database to assign a 
particular M-type to the NSTI S. pyogenes isolates.   
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The enrolled NSTI cases can be divided into three types based on the causative 
pathogen: Infections caused due to diverse set of anaerobic and aerobic bacteria are 
categorized as “Type I” or poly-microbial infections; “Type II” are generally mono-
infections dominated by S. pyogenes whereas “Type III” are infections by Clostridium 
species and are referred to as ‘gas gangrene’ due to gas formation at the site of 
infection. In the INFECT NSTI case collection, type II were seen to be dominating; 
followed by Type I (Figure 4.2A). Among all isolated streptococcal species, isolates 
identified as S. pyogenes (60%) were majoring the isolate collection followed by SDSE 
(15%); together summing up to about 75% (Figure 4.2B). The most frequent emm type 
of S. pyogenes was found to be M1, accounting for about 50% of the S. pyogenes 
collection (Figure 4.2C).     
Within the analyzed NSTI case collection, isolates of the species Streptococcus pyogenes, 
especially of the serotype M1, were most frequently found to be the causative 
pathogen. Therefore the focus of the serologic analysis was set to cases of NSTI mono-
infections with S. pyogenes. Emphasis on determining the antibody titer and their 
protective potential against bacterial toxins would provide insights to the role of 
adaptive immune system in NSTI pathogenesis and would aid in development of more 
targeted therapeutics. Since Intravenous Immunoglobulins (IVIG) is generally given as 
an adjunctive therapy in cases of NSTI with S. pyogenes, it was one of the criteria for the 
selection of cases to be analyzed in this study. Based on the IVIG treatment and disease 
development, cases were differentiated into 3 distinct groups (Table 4.1.2): 
 NSTI cases that received IVIG treatment (IVIG Treated Group) 
 NSTI cases that did not receive IVIG treatment (non IVIG Treated Group) 
 Control group of cases with severe skin/tissue infections, that did not develop 
into an NSTI (non NSTI cases) and therefore also did not received any IVIG 
(Control/Non NSTI Group). 
Analyzing antibody titers and their protective potential against bacterial toxins in these 
groups would provide insights in identifying factors that plays a crucial role in 
development of disease (NSTI cases versus non NSTI cases) and would aid in 
elucidating the role of the serological background in the development of an NSTI. Also, 
the comparison of IVIG-treated and non IVIG treated cases would decipher the efficacy 
of IVIG as an adjunctive therapy. 
 
 
 
Results 
 
67 
 
Table 4.1.2: List of Selected Isolates 
IVIG Treated Group Non IVIG Treated Group Control Group 
2001 3005 6028 
2006 3012 6040 
2015 6016  
2017 6018  
5003 6025  
5004 6026  
5006 6033  
6013   
n = 8 n = 7 n = 2 
The number of cases in each group was dependent on the chronological order of 
arrival of these cases in the two years of collection, thereby differing in the number of 
collected isolates in each group. Hence, the complete serological study was conducted 
on 17 cases: 
 8 IVIG treated NSTI cases 
 7 non IVIG treated NSTI cases  
 2 non NSTI/control cases  
 
The adaptive immune system constitutes specific antibodies that boost the bacterial 
killing by marking the bacterial cells for efficient phagocytosis which might play a 
crucial role in the development/retrogression of a severe NSTI. To investigate if the 
NSTI patient plasma samples carry antibodies against the causative bacterial pathogen, 
and the potential of these antibodies to mediate efficient opsonization and killing, an 
Opsono-Phagocytosis Assay was established. 
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4.2 Detection of antibodies in the INFECT plasma samples  mediating  
      opsonization and killing of bacterial cells in NSTI plasma samples 
Opsonization is a process of pathogen recognition by the host immune system, which 
can be induced and increased by specific antibodies, which mark the bacterial cells and 
induce chemotactic signals for neutrophils and other phagocytic cells of the innate 
immune system to increase the efficiency of eradication by phagocytosis. To investigate 
if the NSTI patient plasma samples carry antibodies against the causative bacterial 
pathogen, and the potential of these antibodies to mediate efficient opsonization and 
killing, plasma samples from the patients recruited in the INFECT project were 
collected by clinical partners at two different time points: Day 0, when a tissue 
infection was rated as NSTI and the patient recruited in the study, and Day 3, which 
was the third day of treatment after the NSTI was identified (Figure 4.3).  
 
Figure 4.3: Time line depicting the time points of plasma collection under INFECT. Plasma samples were 
collected under the project INFECT on two different time points: Day 0 and 3. INFECT cases have been listed along 
with the time span between sample point Day 0 and Day 3. Different groups are shown with different colors: IVIG-
treated (black), non IVIG treated (blue) and control non NSTI group (red). 
From the time-line, it is apparent that all samples named as ‘Day 3’ were collected in a 
Gaussian distribution close to the third day of treatment irrespective of which study 
group they belong to. An Opsono-Phagocytosis assay was established to examine the 
Day 0 and 3 patient’s plasma sample for their potential to opsonize and thereafter kill 
the bacterial cells.  
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4.2.1 Establishment of an Opsono-Phagocytosis Assay 
To investigate the role of the adaptive immune system in the 
development/retrogression of a severe NSTI, the protective potential of the collected 
patient plasma samples against the corresponding bacterial isolate was determined. 
Therefore an Opsono-Phagocytosis Assay was established in which the bacterial cells 
were incubated in the corresponding plasma samples to allow available antibodies to 
bind and mediate opsonization. These opsonized bacterial cells were co-incubated with 
primary human neutrophil granulocytes (Poly-Morpho-Nuclear leukocytes; PMNs) 
and the bacterial killing was measured. As a first test experiment the NSTI isolate 2006 
from the IVIG treated group was incubated with and without IVIG as it is thought that 
IVIG possesses antibodies that are able to recognize various serotypes of S. pyogenes 
and therefore mediate detectable opsonization. The bacterial survival rates were 
calculated after infection with human neutrophils (Figure 4.4). 
 
Figure 4.4: Opsono-Phagocytosis Assay with primary human PMNs using the S. pyogenes NSTI isolate 2006 
in combination with IVIG treatment. Three hour infection of 2×10
6
 cfu/ml of isolate 2006 opsonized in IgG 
depleted human plasma with and without IVIG for 30 min at 37°C in combination with or without 2×10
5
 PMNs. 
Statistical significance was calculated by applying Student’s T-test between detectable cell densities of INFECT 
2006 with and without IVIG (p < 0.05, n=2). 
 
No bacterial killing was mediated in non IVIG opsonized infection as well as in the 
growth controls wherein no PMNs were added. However, a significant decrease in the 
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bacterial cell density was observed in the infection with applied IVIG opsonization 
(Figure 4.4). This validates the functionality of the established Opsono-Phagocytosis 
assay and proves the presence of antibodies reacting specifically against S. pyogenes 
isolates in the applied IVIG mixture. 
4.2.2 Screening  of  INFECT  plasma  samples  using  the  established  Opsono- 
        Phagocytosis Assay 
The established opsono-phagocytosis assay was initially applied on three INFECT 
isolates: Isolate 2001 (IVIG-treated), 6018 (non IVIG treated) and 6028 (non NSTI 
control) (Figure 4.5). 
 
Figure 4.5: Results of the Opsono-Phagocytosis Assay using three bacterial INFECT isolates (2001, 6018 
and 6028) in combination with the corresponding patient plasma samples. Three hours infection of 2×10
6
 
cfu/ml of selected INFECT isolates after 30min opsonization at 37°C in corresponding patient plasma samples (20%, 
diluted in PBS) collected at day 0 and day 3 with 2×10
5
 PMNs. Detectable cfu/ml at time point zero (black bars) and 
after three hours of infection (blue bars) has been depicted in the figure. Infection in presence and absence of IVIG 
in IgG depleted plasma served as positive and negative controls respectively. (p < 0.02, n=2; T-Test). 
As shown in Figure 4.5, no significant reduction in the bacterial cell number could be 
observed for the NSTI isolates 2001 and 6018 when opsonized with the corresponding 
Day 0 plasma. However, the Day 3 patient plasma was able to mediate efficient killing 
for both tested isolates. Contrarily, the Day 0 patient plasma sample of the non NSTI 
control case 6028 was able to opsonize and mediate killing of the corresponding 
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bacterial isolate already on Day 0.  IgG depleted Plasma with and without IVIG served 
as positive and negative controls respectively and verified the previous observations. 
Since the selected patients received antibiotics as therapeutic treatment, a decrease in 
the initial bacterial counts could be observed after incubation with the plasma samples, 
which is a possible explanation for the observed differences between the bacterial 
counting results obtained with the patient plasma and the IgG depleted plasma 
controls.  
The assay was further extended to the selected cohort to address the question if the 
observed effect can be rated as general (Figure 4.6).   
 
Figure 4.6: Results of the Opsono-Phagocytosis Assay of all selected INFECT isolates in combination with 
the corresponding patient plasma samples. (A) Three hours infection of 2×10
6
 cfu of representative INFECT 
isolates after 30 min opsonization at 37°C in corresponding patient plasma samples collected at day 0 (black bars) 
or day 3 (blue bars) with 2×10
5
 PMNs. Percent bacterial survival was calculated by growth controls wherein no 
PMNs were added. (B) A significant reduction in the bacterial cell number when compared to growth control has 
been marked as grey while non-significant titers are marked in red (p < 0.02, n=2; T-Test).  
Out of the 15 analyzed NSTI cases, 14 showed no significant opsonization potential 
against the corresponding bacterial isolate in the Day 0 plasma samples, indicating a 
susceptibility of these patients towards the causative pathogen. Contrastingly, the    
Day 0 plasma sample of the non NSTI case 6028 mediated bacterial killing of the 
corresponding isolate up to 80% and the Day 0 plasma of control case 6040 enabled up 
to 95% killing. Out of all NSTI cases, the plasma sample of the IVIG treated NSTI case 
2015 was the only one that mediated efficient bacterial killing already on Day 0.  
However, all analyzed NSTI cases showed a significant increase in the antibody 
mediated bacterial killing when using the Day 3 plasma samples for opsonization. This 
Is
o
la
te
D
a
y
 0
 P
la
s
m
a
D
a
y
 3
 P
la
s
m
a
2001
2006
2015
2017
3005
3012
5003
5004
5006
6013
6016
6018
6025
6026
6028
6033
6040
C
o
lo
r
T
it
e
r
-
+
Day 0
Day 3
B
a
c
te
ri
a
l 
s
u
rv
iv
a
l 
[%
 g
ro
w
th
 c
o
n
tr
o
l]
Streptococcal Isolates
A. B.
0
10
20
30
40
50
60
70
80
90
100
110
120
130
2001 2006 2015 2017 3005 3012 5003 5004 5006 6013 6016 6018 6028 6025 6026 6033 6040                       
 
Results 
 
72 
 
could be accounted to the applied IVIG treatment or a rapid adaptive immune 
response of the host. Finally, it can be concluded that the adaptive immune system of 
all analysed INFECT NSTI patients is not able to mediate efficient protection against 
the corresponding bacterial isolate during the early stage of infection, where IVIG is 
able to compensate this susceptibility. 
In conclusion, the data generated with the Opsono-Phagocytosis Assay approach 
indicate a crucial role of the adaptive immune system in the development of a severe 
NSTI. All analysed NSTI cases showed a significant susceptibility against the 
corresponding bacterial pathogen during the initial stage of infection whereas the data 
obtained from the analyses of the non NSTI control cases showed protectivity on the 
Day 0 itself. However, bacterial killing does not reduce their detrimental effects as S. 
pyogenes secretes a wide array of exotoxins that remain active and can further 
deteriorate the patient’s condition. To also investigate the protective potential of the 
adaptive immune system against streptococcal exotoxins during the development of an 
NSTI, an ELISA based serology screening was performed. The first step in this serology 
approach was to identify which exotoxins are present in the genomes of the selected   
S. pyogenes INFECT isolates.  
4.3 Detection of Exotoxin genes in the genomes of S. pyogenes INFECT  
      isolates 
It is known that S. pyogenes secretes exotoxins that impair the host immune response in 
different ways like activation of non-specific T-cell sub-populations (superantigens), 
cleavage of IgG (Mac), degradation of chemokines (spyCEP) or inactivation of 
complement system (SIC). Screening for the genes encoding exotoxins in the genomes 
of S. pyogenes INFECT isolates would provide insights on which exotoxin genes are 
prevalent and is a further step towards understanding the influence of the serological 
background in the development of NSTIs.  
4.3.1 Establishment of a Multiplex PCR 
To determine the presence or absence of genes coding for secreted toxins in the 
genomes of the selected S. pyogenes isolates, a multiplex PCR was established. The 
multiplex PCR was set up by modifying and combining previous screening methods of 
Friães et al88 that screened for superantigen genes and Borek et al102 that could amplify 
DNase genes from the genome of S. pyogenes. The established multiplex PCR system is 
able to efficiently detect 21 exotoxin genes within the genomes of S. pyogenes isolates in 
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5 different reactions. The genomic DNA of genome sequenced S. pyogenes strains 
(SF370, MGAS315 and MGAS8232) was used as positive control whereas the genomic 
DNA of the genome sequenced S. gordonii strain Challis (GP204) was used as a 
negative control in all five reactions. Since one strain did not carry all the exotoxins 
amplified in one reaction, a combination of two strains was sometimes used as control 
for a particular reaction (Figure 4.7) 
 
Figure 4.7: Agarose gel picture of all 21 exotoxin genes amplified out of the genomes of selected positive 
controls used in the multiplex PCR. Conserved regions from 21 exotoxin genes were amplified from control 
strains in five different reactions: reaction 1-3 amplifies superantigens while reaction 4-5 amplifies a second set of 
streptococcal exotoxins. The amplified PCR products were separated by size on a 1% agarose gel and stained with 
Ethidium Bromide. Mobility of the bands is expressed in terms of base-pairs (left side) determined by standard 
GeneRuler 1 kB ladder (Fermentas). Each signal in the figure is demarcated by name of the corresponding gene 
being amplified. 
4.3.1 Application of the Multiplex PCR on selected INFECT isolates 
After the successful optimization of the multiplex PCR, it was used to determine the 
presence or absence of exotoxin genes in the genomes of the selected S. pyogenes 
INFECT isolates (Table 4.3.1). 
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Table 4.3.1: Repertoire of exotoxin genes within the genomes of selected S. pyogenes 
INFECT isolates 
 
The screening for exotoxin genes in the genomes of S. pyogenes INFECT isolates 
showed that some of the exotoxins are distributed in a serotype specific pattern. Out of 
the 21 exotoxins, 11 Streptococcal pyrogenic exotoxins have super antigenic 
properties: they can cause nonspecific activation of copious amount of T-cells. 
Interestingly, only the gene coding for the superantigen SpeG was present in all the 
tested S. pyogenes isolates, while other superantigen genes like speJ, speK, speL and speM 
were not restricted to any specific serotype. The gene coding for SpeA and SmeZ were 
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the most abundant superantigens, covering about 93% and 60% of S. pyogenes isolates 
respectively, while the speC and speH genes were the least common. SpeB was initially 
thought to be a superantigen but was later found to be a Cysteine-Protease103. The gene 
coding for SpeB could also be detected in all the tested S. pyogenes isolates, irrespective 
of the serotype of the isolate. DNases are known to degrade extracellular traps released 
by neutrophils (NETs) and hence are important for the escape of entrapped bacteria56. 
While the gene coding for SpeF (mitogenic factor) and SdaB were recurring in all 
isolates, others were sporadic. Interestingly, the sdc and sdaD genes were seen 
excluding each other; the former being present only in one of the INFECT isolates 
(INFECT 2015). The genes of the immune-modulating exotoxins, scpA and spyCEP 
were always present while the genes coding for Mac and SIC did not show any 
serotype specificity.  
To investigate the degree of similarity among different S. pyogenes isolates based on the 
distribution of detected exotoxin genes and the serotype determined by M-typing, a 
resemblance matrix was generated within the three selected groups (IVIG-treated,  
non IVIG treated and non NSTI control group) (Figure 4.8).  
 
Figure 4.8: Dendrographic plot of a resemblance matrix of S. pyogenes INFECT isolates based on their 
genetic exotoxin profile. The resemblance matrix was generated by S17 Bray Curtis method calculating the group 
average values. IVIG treated cases are highlighted in black, non IVIG and non NSTI cases are highlighted in blue 
and red respectively. The corresponding M-type is given in parenthesis. 
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Most of the S. pyogenes INFECT isolates of a particular serotype clustered together, thus 
showing a high similarity quotient within the serotype. Interestingly, there was no 
distinct clustering within different groups (IVIG treated NSTI isolates, non IVIG 
treated NSTI isolates and non NSTI control cases) being studied.  
Most of the screened S. pyogenes exotoxin genes are present in various Single 
Nucleotide Polymorphism alleles (SNP). Despite these polymorphisms, they possess 
conserved structure with no change in function or epitope. For example, the gene 
coding for streptokinase, Ska, is ubiquitously present in genomes of all S. pyogenes 
isolates and is found to occur in three different forms: ska-1, ska-2a and ska-2b. These ska 
subtypes have different mechanism of action for plasmin activity formation51. For the 
determination of ska types present in the genomes of the analyzed INFECT isolates, the 
ska gene was sequenced and a dendogram based on sequence comparisons was 
constructed (Figure 4.9). 
 
Figure 4.9: Dendogram visualizing different clusters of the ska gene as obtained by sequence comparison. 
The variable region of the ska gene was sequenced from all selected INFECT S. pyogenes isolates and a 
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dendogram was generated by sequence comparison using ClustalW (Number of Bootstraps=1000). IVIG treated 
patients are marked in black, non IVIG in blue and non NSTI controls in red. The reference sequences for different 
clusters are marked in grey and were obtained from McArthur et al 
51
.  
The ska gene of all analyzed isolates belonged to Cluster 1 or 2a. The obtained 
sequences of INFECT isolates belonging to cluster 2a were 100% similar to the 
reference sequences of S. pyogenes SF370 and S. pyogenes MGAS5448 whereas there 
were differences in percent similarities in cluster 1, ranging from 100% to as low as 53% 
with the reference sequences. Interestingly, the presence of ska gene of cluster type 2b 
could not be observed in the genomes of the analyzed S. pyogenes isolates.  
The screening for presence or absence of exotoxin genes in the genomes of S. pyogenes 
isolates provides an insight of which exotoxin genes may play a critical role in the NSTI 
scenario. Therefore all detected exotoxins (n=18) were either cloned purified or 
purchased if commercially available to determine corresponding antibody titers in the 
plasma samples of the selected INFECT cases. 
4.4 Detection of antibodies against exotoxins in INFECT plasma samples 
The host adaptive immune response is crucial for the efficient identification and 
elimination of pathogens. Specific antibodies are able to boost the process of 
eradication of the pathogen by initiating efficient opsonization of the bacteria and by 
neutralizing bacterial toxins. To further investigate the role of the adaptive immune 
system during the development of an NSTI, an extensive serology approach was 
performed wherein antibody levels against exotoxins were measured in plasma 
samples of NSTI and non NSTI patients. Therefore all streptococcal exotoxins 
identified by the multiplex PCR screening could to be potentially involved in the 
pathogenesis of the analyzed INFECT cases and therefore, were, if not commercially 
available cloned and purified to be used in an ELISA system.  
4.4.1 Cloning and Purification of Exotoxins 
The results of the established multiplex PCR clearly showed which exotoxin genes are 
present in the genomes of the selected S. pyogenes INFECT isolates. To measure 
antibody titers against these exotoxins in the collected plasma samples all genes, if not 
commercially available toxins, were cloned in the pQE30-TEV vector in an E. coli M15 
background, overexpressed and the corresponding exotoxin purified (Figure 4.10).  
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Figure 4.10: Electrophoretic gel pictures of exotoxin gene cloning and protein purification. (A) Selected 
exotoxins were cloned in pQE30-TEV vector (Lane 1). For this, the exotoxin genes (Insert) were amplified by PCR 
(Lane 2) using primers that contained restriction sites for BamHI and SalI. The insert and Vector were double 
digested with BamHI/SalI (Lane 3) and ligated using T4 DNA Ligase (Lane 4). The ligated products were 
transformed in E. coli M15 cells. Different lanes have been demarcated with the product as analyzed on 1% Agarose 
gel electrophoresis, stained with Ethidium Bromide. The sizes of the fragments were estimated by comparison with 
Standard DNA Ladder (1 kB GeneRuler). (B) The expression of the cloned exotoxin genes were induced with 1mM 
IPTG (Lane 1 and 2). The cells were lysed using French Press and the cell debris was removed by centrifugation. 
The cell lysate (Lane 3) was incubated with Ni
2+
-NTA Sepharose beads for protein binding. The proteins were 
purified by washing thrice with wash buffer containing 20 mM Imidazole and elution with 250 mM Imidazole (Lane 4). 
The proteins were analyzed with 10% SDS-PAGE, stained with Coomassie. The sizes of the fragments were 
estimated by comparison with standard protein ladder. Here, the cloning, overexpression and purification of SpeA 
(Superantigen) has been shown as an example.   
Some of the exotoxins (SpeB, Mac, SLO and Hyl) were purchased from commercial 
sources. Since the bacterial exotoxins are overexpressed and purified in an E. coli 
background, there are possible contaminations with the E. coli proteins that could 
result in false positive antibody titres. To control this possible E. coli background 
contamination, the empty pQE30-TEV vector was cloned and the protein background 
pattern, that unspecifically binds to the used Ni2+-NTA Sepharose was purified and 
diluted in the same way as the target exotoxin and served as the ‘background’ control.  
4.4.2 Establishment of an ELISA detection system for exotoxin specific antibodies  
After cloning and purification of streptococcal exotoxins, an efficient detection system 
to identify IgG titers against the purified exotoxins in the NSTI patient’s plasma was 
essential. Therefore, an Enzyme-linked Immunosorbent Assay (ELISA) was 
established. ELISA is a common laboratory technique that can be used to measure the 
concentration of an analyte by using enzyme immunoassays. An ELISA is a multi-step 
Construction
Empty
pQE30-TEV
Cutted
pQE30-TEV
PCR
Product
Ligated
Construct
1000
3000
500
10000
F
ra
g
m
e
n
t 
s
iz
e
 [
b
p
]
Cell
Lysate
Purified
Protein
After
Induction 
Before
Induction 
25
F
ra
g
m
e
n
t 
m
a
s
s
 [
k
D
a
]
15
35
55
75
100
130
Purification
A. B.
 
Results 
 
79 
 
process that involves at least one antibody with specificity for a particular antigen. The 
analyte (either an antigen or an antibody) is immobilized/coated by adsorption to a 
polystyrene 96 well plate. Coating is followed by a blocking reaction wherein all the 
unoccupied surfaces of the well material are captured by a non-interacting protein. The 
detection antibody is added, forming a complex with the antigen. The detection 
antibody can be covalently linked to an enzyme, or can itself be detected by 
a secondary antibody that is linked to an enzyme through bioconjugation. Between 
each step, the plate is washed using a mild detergent solution to remove proteins or 
antibodies that are non-specifically bound. After a final washing step, the plate is 
‘developed’ by adding an enzymatic substrate to produce a detectable signal, which 
indirectly indicates the quantity of the analyte in the sample. Hence, establishing an 
ELISA needs optimization of various factors: amount of analyte being coated, dilutions 
of primary and secondary antibody, concentration of enzymatic substrate (ABTS), all in 
accordance with the linear range of detection system (Varioscan) (Figure 4.11).  
 
Figure 4.11: Schematic depiction of various parameters to be addressed during the establishment of an 
ELISA system. The standardization of an ELISA requires optimization of four factors all influencing each other: the 
exotoxin coating, the dilution of primary antibody (plasma), the concentration of the secondary antibody, and the 
ABTS concentration. The already fixed parameter (Detector’s Linear Range) has been highlighted in blue. 
 Linear Range of the Detector: The secondary antibody was conjugated with Horse 
Radish Peroxidase (HRP), hence ABTS [2,2'-azino-bis(3-ethylbenzothiazoline-6-
sulphonic acid)] was used as a substrate. ABTS changes color from light green to 
dark green with an absorption maximum around 416 nm after chemical conversion 
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by HRP. The linear range of the selected detector (Varioscan) to measure absorption 
at 416 nm as stated by the manufacturer reached from 0.0 to 4.0.  
 
 ABTS concentration and Secondary Antibody dilution: To cover the complete 
linear range of the detection system, the ABTS concentration as well as the 
concentration of the secondary antibody should not be limiting factors. To estimate 
the optimal dilution of the secondary antibody and ABTS concentration, a double-
gradient experiment was performed (Figure 4.12).   
 
Figure 4.12: Dependency of secondary antibody dilution and ABTS concentration towards the signal 
intensity obtained by the ELISA system. A double gradient of secondary antibody dilution and ABTS 
concentration was performed. Different dilutions of HRP labeled secondary antibody were added to varying 
concentrations of ABTS in order to estimate the optimum secondary antibody-ABTS combination. The graph was 
plotted as gradient of ABTS concentration (in µg/ml) versus optical density (Absorbance measured at 416 nm). 
Different graphs depict different secondary antibody dilutions. The linear correlation of the selected antibody dilution 
was calculated and is shown next to the corresponding graph. A dotted horizontal line indicates the upper limit of 
linear range of the detection system.   
Higher secondary antibody dilutions (1:2000 and 1:3000) were not sufficient to receive 
a signal intensity, that covers the complete dynamic range of the detection system, 
while the lowest antibody dilution (1:500) was able to produce a sufficient signal 
intensity with a minimum of 400 µg/ml of ABTS, but with the drawback of increased 
experimental costs. Hence, 1:1000 (0.2 µg/ml) was selected as the optimum dilution for 
the secondary antibody in combination with an ABTS concentration of 800 µg/ml.  
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 Concentration of Exotoxin protein coating: Once the optimal ABTS concentration 
and secondary antibody dilutions were fixed, the next variable to be optimized was 
the amount of analyte being coated. To estimate the optimal antigen concentration 
required for coating, a gradient of different protein concentrations was used. For 
this, the His-tag of the exotoxins was targeted to simulate an exotoxin specific 
antibody response (Figure 4.13).  
 
Figure 4.13: Dependency of the coating protein concentration towards the received ELISA signal intensity. A 
concentration gradient of His-tagged protein coated to the ELISA plate well was analyzed in the ELISA system. The 
coating was done by incubating the ELISA plate wells with different concentrations of protein in PBS (50 µl) 
overnight at 4°C. The standardized secondary antibody dilution (1:1000) and ABTS concentration (800 µg/ml) in 
combination with a mouse Anti-His antibody (dilution of 1:1000) as primary antibody was used in this experiment. 
The graphs were plotted as gradient of coated protein concentration (in µg/ml) versus the obtained optical density 
(Absorbance measured at 416 nm). The protein concentration selected for coating is highlighted in red. A dotted 
horizontal line depicts the upper limit of linear range of the detection system.   
The applied concentration gradient of coated protein showed a linear effect towards 
the optical density measured at 416 nm. The system reached the maximum possible 
range at a minimum concentration of 2.5 µg/ml of protein. To avoid the limiting effect 
of the coated analyte concentration, 3 µg/ml was selected for the ELISA.  
 Plasma (Primary Antibody) Dilution: The ELISA was established by determining 
optimal concentrations of all variables viz. coating of the antigen, secondary 
antibody concentration, ABTS concentration, all in accordance with the dynamic 
range of the detector. The primary antibody (plasma) concentration was the only 
variable left in this system that needs to be adjusted to a reasonable value. Since the 
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plasma of the selected NSTI patients is a limiting factor, a primary antibody 
(plasma) dilution of 1:50 was used. This concentration allowed an optical density to 
cover the complete dynamic range of the system with the established parameters 
(Figure 4.14).  
 
Figure 4.14: Schematic depiction of all parameters standardized in the established ELISA system. All 
parameters influencing the antibody detection capabilities of the established ELISA system are listed along with their 
optimized values in parenthesis. 
4.4.3 Verification of established ELISA system 
To test the potential of the established ELISA system (Section 4.4.2) in the detection of 
antibodies specific to different streptococcal exotoxins, an antibody mixture usually 
given as Intravenous Immunoglobulin treatment (IVIG) was used. IVIG are thought to 
contain antibodies specific to various serotypes of S. pyogenes as well as the complete 
spectrum of streptococcal exotoxins. 5 mg/ml of IVIG was used in accordance to the 
standardized protocol of the clinical trial called INSTINCT (Immunoglobulin for 
Necrotizing Soft Tissue Infections: a Randomized Controlled Trial) at Rigshospitalet 
Denmark (Trial Number NCT02111161). This clinical trial is a randomised study to 
evaluate the efficacy and efficiency of IVIG being administered to NSTI patients 
compared to a placebo treatment. Our study has been set in accordance to the 
INSTINCT programme, using the same manufacturer and concentration of IVIG as 
done within this programme. Since the bacterial exotoxins are overexpressed and 
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purified in an E. coli background, there are possible contaminations with the E. coli 
proteins that could provide false positive antibody titres (Figure 4.15).  
 
 
Figure 4.15: Bar graph diagram depicting the antibody titers against exotoxins in IVIG as detected by the 
established ELISA. The established ELISA system was tested for its potential to detect antibodies specific for 
streptococcal exotoxins using 5 mg/ml IVIG as the primary antibody. 3 µg/ml of each exotoxin were coated on 96 
well high binding ELISA plate. Already standardized secondary antibody dilutions (1:1000) and ABTS concentrations 
(800 µg/ml) were used. To control the background (E.coli) titer, an empty vector protein purification was used in the 
same dilution as the target exotoxin. The relative antibody titer (Absorbance at 416 nm) was plotted against each 
exotoxin and its corresponding E.coli background. The statistical significance testing between relative antibody titer 
of exotoxin when compared to background E. coli protein, was done by applying an ANOVA test with a p value cutoff 
set to 0.05 (n=2) and are marked with red asterisks.  
 
To control the possible E. coli background contamination, the empty pQE30-TEV vector 
was cloned and the protein background pattern, that unspecifically binds to the used 
Ni2+-NTA Sepharose was purified and diluted in the same way as the target exotoxin. 
The established ELISA system was able to detect significant antibody (IgG) titers in the 
tested IVIG dilution against all 18 exotoxins (p < 0.05, ANOVA, n=2). This confirmed 
not only the presence of specific antibodies against streptococcal exotoxins in the used 
IVIG product, but also the potential of the established ELISA system to detect IgG titers 
against streptococcal exotoxins in human plasma samples.  
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4.4.4 Determination of antibody titers in INFECT plasma samples 
After the establishment and validation of the ELISA system was successfully 
concluded, it was ready to be used with INFECT patient plasma samples to identify 
antibodies titers against the selected streptococcal exotoxins. The plasma samples to be 
analysed were collected by the INFECT clinical partners at two different time points : 
Day 0, when a tissue infection was rated as NSTI and the patient recruited in the study, 
and Day 3, which was the third day of treatment after the NSTI was diagnosed (Section 
4.2, Figure 4.3).  
Initially, the established ELISA system was tested on one set of plasma samples from 
each group: INFECT NSTI case 5006, which was IVIG treated, INFECT NSTI case 6018 
that was a non IVIG treated patient and INFECT case 6028 which was a member of the 
control group of non NSTI patients (Figure 4.16).  
Figure 4.16: Bar graph diagram depicting relative antibody titers against 11 superantigens in the plasma 
sample sets of three selected INFECT cases. The established ELISA was used to analyze the Day 0 and Day 3 
plasma sample sets of three selected INFECT cases, one from each group (IVIG-treated, non IVIG treated and non 
NSTI case) to detect antibody titers against all 11 streptococcal superantigens. Relative antibody titers were 
detected against superantigens on Day 0 (blue bars) and Day 3 (black bars). A statistical significance test was 
performed against the background E. coli empty vector purification (p < 0.05, n=2; ANOVA). Significant titers, when 
compared with the background control, are marked with red asterisks. 
As shown in Figure 4.16, the initial antibody titers in the Day 0 plasma samples against 
11 streptococcal superantigens were rare in NSTI patients as compared to the non NSTI 
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control. The Day 0 plasma sample of the NSTI case 5006 showed a significant antibody 
titer only against SpeC, while the plasma of NSTI case 6018 had no significant titers at 
all on Day 0. Contrarily, the non NSTI control case 6028 showed significant antibody 
titers against 9 of the 11 tested superantigens (SpeA, SpeC, SpeG, SpeH, SpeI, SpeJ, 
SpeK, SpeM, SSA and SmeZ) in the Day 0 plasma sample. On Day 3, there was a 
significant increase in the presence of antibody titers against all superantigens in the 
plasma sample of the NSTI case 5006, probably due to the applied IVIG treatment. The 
non IVIG treated NSTI case 6018 developed significant antibody titers only against 3 of 
the 11 tested superantigens (SpeA, SpeG and SmeZ); while no change in the antibody 
titer pattern of the control 6028 could be observed. The comparative analysis of these 
three cases provided an insight to the adaptive immunological susceptibility of NSTI 
patients at Day 0 compared to non NSTI cases. All Day 0 plasma samples of NSTI cases 
lacked antibody titers against most of the tested superantigens, which is the opposite of 
what could be observed in the Day 0 plasma sample of the non NSTI control case. 
Additionally, the applied IVIG treatment was able to compensate the detected lack of 
antibody titers, which could be seen in the analysis of the Day 3 plasma sample of the 
IVIG treated case 5006. 
These results confirmed the successful establishment of the ELISA system to detect IgG 
titers against streptococcal exotoxins in NSTI patient’s plasma samples. Hence, the 
ELISA based analysis was extended to the remaining samples of the cohort including 8 
IVIG treated NSTI cases, 7 non IVIG treated cases and 2 non NSTI control cases. 
These results were compiled with the PCR data obtained through multiplex PCR to be 
able to examine significant pattern of particular exotoxin genes in combination with the 
presence of antibody titers against the corresponding toxin in all three study groups 
(Figure 4.17). 
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Figure 4.17: Serologic analysis of selected INFECT NSTI and non NSTI cases against streptococcal 
exotoxins of the corresponding isolate. Relative antibody titers of 11 superantigens (A) and a second set of 7 
exotoxins (B) in Day 0 (left grid) and Day 3 (right grid) patient plasma samples combined with the Multiplex PCR 
results, for 8 IVIG treated cases, 7 non IVIG treated cases and 2 non NSTI control cases. Plasma IgG titers against 
a streptococcal exotoxin calculated as statistical significant against the corresponding E. coli purified empty vector 
background control (p<0,05, n=2) that matches to a positive PCR result within the genome of the corresponding 
bacterial isolate are marked with blue squares. Not significant titers against an exotoxin, whose gene was identified 
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in the genome of the corresponding pathogen during the screening PCR, are marked with red squares. Significant 
titers against a superantigen not present in the corresponding bacterial genome are marked with grey squares. The 
INFECT case number is given on the left vertical axis while the M-type of the corresponding streptococcal isolate is 
shown on the right vertical axis. The different analyzed exotoxins are given on top of each grid. The selected 
INFECT cases are sorted by their groups: IVIG-treated NSTI cases, non IVIG-treated NSTI cases, and non NSTI 
control cases. 
The compiled results showed that the adaptive immune response plays a crucial role in 
development/retrogression of NSTI. All analysed NSTI cases lacked a specific antibody 
titer against at least one of the exotoxin present in the genome of the corresponding 
isolate and therefore very likely involved in the NSTI pathogenesis. Contrarily, the  
non NSTI control cases showed significant antibody titers against all superantigens 
present in the genome of the causative pathogen. Since IVIG is a solution of 
concentrated antibodies from healthy donors, it was able to compensate for the 
deficiencies of exotoxin specific antibodies in IVIG treated NSTI patients, as seen on the 
Day 3 samples. For non IVIG treated patients, raised antibody titer against only a 
subset of exotoxins (SpeA, SpeG, SSA, SmeZ, as well as SIC, SpeB, Mac, SLO, and Hyl) 
could be observed in the plasma samples taken on the third day of infection. 
Interestingly, no change in the antibody response was seen against SpeH, SpeI, SpeJ, 
SpeK, SpeL, SpeM, and Ska in any of the non IVIG cases, while the antibodies against 
Ska-1 and Ska-2a could not be differentiated by the developed ELISA system. To 
conclude, all patients that developed an NSTI, lacked titers against at least one of the 
streptococcal exotoxins present in the genome of the corresponding bacterial isolate in 
the Day 0 plasma samples. Contrarily, the plasma samples of the non NSTI control 
patients showed antibody titers against all necessary exotoxins, already on Day 0. The 
next step in the serological approach was to determine if the antibody titers, detected 
in the patient’s plasma, were mediating protectivity against their respective exotoxin. 
To start with the analysis, the superantigens were selected as a first subset of exotoxins. 
Therefore, a T-cell Proliferation Blocking Assay was established that would provide 
insights in the activity of the purified superantigens and the potential of the identified 
antibody titers to block the toxin function. 
4.5 Determination of protectivity of the detected antibody titers against  
      superantigen function 
Antibodies specific for a particular exotoxin are potentially able to block its toxic effects 
by binding to its active site, thereby neutralizing the toxin and providing ‘protectivity’ 
to the host. As already mentioned, superantigens specifically target T-cells, leading to a 
non-specific activation of large amounts of T-cells through binding and cross-linking 
MHC-II receptors on antigen presenting cells with T-cell receptors (TCR), thus forming 
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a MHCII-SAg-TCR complex. To evaluate if the detected antibody titers are mediating 
protectivity against all analyzed superantigens, a T-cell Proliferation Assay was 
established.  
4.5.1 Development of a T-cell proliferation Assay 
T-cells are an active part of the adaptive immune system and generally activated by 
specific antigens. Superantigens, on the other hand, lead to an unspecific activation of a 
huge subset of T-cells to distract the host immune system from establishing an 
adaptive response. A proliferation assay with human T-cell was established to analyze 
the protectivity of the detected antibody titers in the plasma samples. As a first step, a 
two-fold dilution series of all 11 superantigens was tested towards their potential to 
mediate unspecific T-cell proliferation (Figure 4.18).   
 
 
Figure 4.18: T-cell proliferation Assay to test the in vitro stimulation of human T-cells by 11 streptococcal 
superantigens. The proliferation of human primary T-cells derrived from two different healthy donors by 11 
streptococcal superantigens was measured. A two fold dilution series of different superantigens in PBS was 
prepared and added to 2×10
6
 purified human T-cells and incubated at 37°C with 5% CO2 for 6 days. The T-cell 
proliferation was estimated using an MTT based assay. Human Serum Albumin was used as a non-stimulating 
negative control. The relative T-cell proliferation was plotted against the concentration of the corresponding 
superantigen (in µg/ml). The concentration of superantigens for which the highest response was the obtained 
(marked with a red circle) was used as defined concentration for furher experiments. 
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In most of the cases, the T-cell proliferation shows a parabolic effect with the increasing 
concentration of the tested superantigen, which clearly indicates the functionality of all 
purified superantigens. For each tested superantigen the concentration, where the 
stimulating effect towards unspecific proliferation of T-cells reached its maximum was 
determined and used for further experiments. For SpeA, SpeC, SpeH, SpeL and SpeM, 
a concentration of 32 µg/ml was selected whereas for SpeG, SpeI, SpeJ, SpeK, SSA and 
SmeZ, 16 µg/ml was selected for further experiments. 
4.5.2 Development of a T-cell Proliferation Blocking Assay  
To investigate the protective role of the antibody titers detected in the INFECT plasma 
samples, a Blocking Assay was established, which based on the determined maximum 
cellular proliferation concentration of each of the 11 streptococcal superantigens. The 
results of the analysis of IVIG treated NSTI case plasma samples with the established 
ELISA system suggests that IVIG carries significant antibody titers against all tested 
superantigens (Section 4.4.3). Therefore, a set of different dilutions of IVIG,                   
co-incubated with the determined maximum proliferation concentration of each 
superantigen was used to measure the percentage of inhibition of each superantigen 
activity (Figure 4.19).  
 
Figure 4.19: Bar graph depicting the blocking activity of antibodies in IVIG against 11 streptococal 
superantigens. Superantigens were diluted in selected concentrations in IgG depleted plasma and co-incubated 
with different dilutions of IVIG (100% = 5 mg/ml) for 1 hour at room temperature. Subsequently 2×10
6 
purified human 
T-cells were added to the Superantigen-IVIG mixture and incubated at 37°C with 5% CO2 for 6 days. The T-cell 
proliferation was estimated using an MTT based Assay. IgG depleted plasma containing the same amount of human 
serum Albumin was set as negative control and the percentage of inhibition was calculated by substracting the 
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obtained IVIG blocking values with the proliferation values of T-cells with human albumin. Different concentrations of 
IVIG are depicted in black bars. Blue bars represent the concentration of IVIG selected for further experiments. 
A concentration dependent inhibition of the superantigen activity by antibody 
mediated blocking of IVIG was observed. 100% IVIG (5 mg/ml) was able to completely 
block all superantigen activity except SpeA. As previously described, complete 
inhibition of SpeA cannot be achieved in this set up104. 5% IVIG and 10% IVIG were not 
able to completely block the activity of the tested superantigens. However, 20% IVIG 
showed the same effect in vitro as 100% IVIG with respect to its blocking efficiency. 
Thereafter, 20% IVIG in IgG depleted human plasma was used as positive control in 
further experiments.  
4.5.3 Determination of the protectivity against superantigens of antibody titer 
detected in NSTI case plasma samples 
The established T-cell Proliferation Blocking Assay was used to determine the 
protection potential of detected antibody titers in NSTI patient plasma sample sets. 
Due to constraint of limited plasma sample volume, only a few selected cases from the 
cohort were used in this approach. The blocking assay was initially tested on two 
INFECT cases: 5006 (IVIG treated group) and 6018 (non IVIG treated group) (Figure 
4.20). 
 
Figure 4.20: Blocking of superantigen activity by antibodies from NSTI patient plasma samples of two 
selected INFECT cases. Superantigens were diluted in selected concentrations in INFECT patient’s plasma (20%, 
diluted in PBS) for 1 hour at room temperature. 2×10
6 
purified human T-cells were added to the Superantigen-
INFECT patient plasma mixture and incubated at 37°C with 5% CO2 for 6 days. T-cell proliferation was estimated 
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using a MTT based Assay. IgG depleted plasma containing the same amount of human serum Albumin was set as 
negative control and the percentage of inhibition was calculated by substracting the obtained antibody blocking 
values with the proliferation values of T-cells with human albumin. Percentage inhibition of 11 streptococcal 
superantigens by 20% Day 0 plasma is indicated in blue bars and of 20% Day 3 plasma in black bars. 
In the Day 0 plasma samples of the two selected NSTI cases no significant blocking 
activity could be observed, except a 100% functional inhibition of SpeC by the plasma 
of the case 5006. However, the Day 3 plasma sample of this case showed 100% 
antibody mediated blocking of all superantigens, except SpeA, whose function was 
inhibited by around 70%. This increase of antibody mediated blocking of the T-cell 
proliferation inducing function of the tested superantigens could be explained by the 
applied IVIG treatment. IVIG was obviously able to compensate the observed 
deficiencies in antibody titers and antibody mediated protectivity. In the Day 3 plasma 
samples of the non IVIG treated NSTI case 6018 protective antibody titers could only be 
detected against SpeA, SpeG and SmeZ.  
The proliferation assay was extended to a subset including the plasma samples of three 
IVIG treated cases (5004, 5006 and 6013) and two non IVIG treated cases (6016 and 
6018) (Figure 4.21). 
 
Figure 4.21: Antibody mediated blocking activity of NSTI plasma samples against 11 streptococcal 
superantigens. Percentage inhibition of 11 streptococcal superantigens by 20% Day 0 (left grid) and Day 3 (right 
grid) plasma was calculated against 20% IgG depleted plasma. Blue squares are marked in case of 100% blocking, 
grey squares show more than 90% inhibiton and red squares depict inhibition less than 90%.    
All detected antibody titers were able to block the superantigen activity by more than 
90%, except for SpeA wherein inhibition above 80% was not possible.  
To generate a comprehensive overview about the presence of exotoxin genes in the 
genomes of the analysed INFECT isolates (Section 4.3), in combination with the 
antibody titers detected in the corresponding patient plasma samples (Section 4.4) and 
the determined antibody mediated protection against these toxins(Section 4.5), the 
results obtained with  the developed ELISA system were linked to the results of the T-
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cell proliferation blocking assay, and combined with the Multiplex PCR screening 
results (Figure 4.22).  
 
 
 
Figure 4.22: Comparative plot combining the results of antibody titer screening by the ELISA system, 
antibody mediated superantigen blocking determined by T-cell proliferation, and the exotoxin gene 
screening by Multiplex PCR. Antibody titers and their protection potential of three representative IVIG and two non 
IVIG treated cases were studied. The upper grid shows the detected antibody titers determined by ELISA in 
combination with the results of the bacterial Multiplex PCR genome screening. Plasma IgG titers that are considered 
to be significant (p < 0.05, n=2; ANOVA) are shown as blue square (including a positive PCR result). In case of no 
significant titer but a positive PCR result, the squares are colored red. While, a positive antibody titer but no 
corresponding gene in the genome of the causative bacterial isolate is marked in grey. The lower grid displays the 
protection potential of the detected antibodies against 11 streptococcal superantigens measured by the established 
T-cell proliferation blocking assay. Blue squares are marked in case of 100% inhibition of superantigen function 
when the gene coding for the corresponding superantigenis present in the genome of the causative bacterial isolate. 
Red squares depict that there was no inhibition when the corresponding gene was present, while grey squares show 
that there was an antibody mediated inhibtion but no corresponding gene present. Numbers given in red squares 
represent the percentage of inhibition values compared to the positive control treated with IgG depleted human 
plasma. 
 
On comparative analysis of antibody titers detected with the ELISA system and their 
protection potential against the superantigen function determined by the T-cell 
proliferation blocking assay, it was quite apparent that all detected IgG titers 
considered as statistical significant when compared to the background control were 
mediating 100% protection against the corresponding superantigen, with the exception 
of SpeA, which cannot be blocked completely. If these results are extrapolated to other 
NSTI and non NSTI patients, the detected antibody titers in the Day 0 plasma samples 
of the analyzed non NSTI control patients could most probably inhibit the function of 
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most superantigens probably produced by the corresponding S. pyogenes isolate during 
the initial stage of infection, while the NSTI cases suffered from a fatal serologic 
susceptibility towards the superantigen repertoire of the causative pathogen. Hence it 
can be concluded, that the adaptive immune response against streptococcal exotoxins, 
especially against superantigens also plays a crucial role in development of a severe 
NSTI. 
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5. Discussion 
Necrotizing Soft Tissue Infections (NSTIs) like necrotizing fasciitis (NF) are life 
threatening infections of the deeper layers of skin and subcutaneous tissue, spreading 
across the fascia1. NSTIs are generally associated with medical risk factors like diabetes 
mellitus, cardiovascular disease, or recent surgery, but also with small wound 
infections or trauma and have a mortality rate of 12-35%, when properly treated5. It is 
often difficult to diagnose an NSTI due to its close symptomatic similarities with 
cellulitis, during early days of infection, thus posing a threat to life of the patient due to 
delays in specialized treatment and simultaneous rapid spread of the pathogen105. NSTI 
affected patients need intensive care unit treatment with rigorous medication, surgery 
to remove infected tissue and specialized treatment strategies like HyperBaric Oxygen 
therapy (HBO) and IntraVenous Immuno-Globulin administration (IVIG). IVIG is a 
sterile preparation of concentrated antibodies recovered from the pooled serum of at 
least 1000 healthy donors that is discussed to work by a variety of mechanisms like 
activation of complement, facilitation of opsonisation, and neutralization of bacterial 
toxins, and therefore frequently applied by NSTIs although a positive effect on the 
recovery of affected patients has not been shown yet. 
The development of an NSTI is a complex interplay between the host immune system 
and the invading pathogen that produces various virulence factors and exotoxins with 
which it is able to manipulate or evade the immune response. Generally, the first line 
of defense is provided by the innate immune system as an initial response against the 
invading pathogenic bacteria. However, along with the innate immune system, the 
second line of defense, the adaptive immune system, is activated and provides specific 
antibodies, which help boosting the innate immune response through mediating 
opsonization of bacteria and toxin neutralization. Antibody dependent opsonization of 
bacteria by the complement system acts as chemoattractant towards phagocytic cells of 
the innate immune system like neutrophils and thus increases the recognition and 
phagocytic clearance. Consequently, the lack of specific antibodies against invading 
bacterial pathogens and against bacterial toxins could represent a risk factor for the 
development of a severe NSTI. In this perspective, the here presented study was 
designed to investigate the contribution of the host immune system, especially the 
adaptive immune system, particularly focusing on the NSTI scenario. Therefore, cases 
of Necrotizing Fasciitis were recruited and the corresponding bacterial isolates were 
collected under the European Union funded project named INFECT 
(http://www.fp7infect.eu/). In parallel, control cases were enrolled wherein patients 
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suffered from severe skin and tissue infections that did not develop a necrotic stage. As 
a starting point, all collected INFECT cases within the time frame of two years (2013-
2015), were typed on the basis of the causative pathogen. This allowed the distribution 
of the collected NSTI cases into three subtypes: type I, caused by a diverse mixture of 
different bacterial species; type II mainly caused by Streptococcus pyogenes and type III, 
caused by Clostridium species. This typing confirmed the complicated nature of NSTIs 
caused by bacteria, which are quite diverse. However, type II infections, dominated by 
S. pyogenes, were found most frequent compared to others subtypes of NSTIs. These 
results have been in agreement to previous studies106. Hence, the main focus of this 
study was set to the investigation of type II NSTIs caused by S. pyogenes. Therefore, 
various specialized typing methods were applied, which confirmed the species 
affiliation of all analyzed S. pyogenes INFECT isolates by their β-hemolytic behavior 
and their expression of the ‘A’ antigen on the bacterial surface. Furthermore, all S. 
pyogenes isolates were characterized based on their M-protein (emm gene), a surface 
bound virulence related protein and the primary antigen of S. pyogenes29. Sequence 
driven comparisons of the emm gene (M-typing) further classified the S. pyogenes 
INFECT isolates by different serotypes (M-types). A dominance of isolates of the 
serotype M1 in the analyzed collection was observed, which is in accordance to other 
publications that suggest the geographical dominance of S. pyogenes M1 in 
Scandinavian countries107,108,109,110. The serotype M1 has been seen to procure the ability 
to undergo rapid changes in severity and the disease frequencies111,112. However, the 
exact reason for its dominance still remains undetermined.   
The human innate and adaptive immune system comprises of vast variety of cells and 
proteins that work in a well-coordinated manner during the course of an infection. In 
this perspective, antibodies perform a crucial function in bacterial clearance and toxin 
neutralization. Due to such indispensable role of antibodies, IVIG that are concentrated 
antibodies, are generally given as an adjunctive therapy in case of an NSTI caused by   
S. pyogenes. However, administration of IVIG is the sole choice of the physician treating 
the patient, thereby some patients receiving it and others not. Even though there are 
many reports that prove IVIG contains protective antibody titers against S. pyogenes, its 
efficacy in the NSTI scenario still remains ambiguous. IVIG treatment, in addition, is 
expensive and might not only cause mild side effects like fever but also severe 
repercussions such as anaphylaxis and renal failure. Taking the assets and drawbacks 
of IVIG as a specialized treatment during the acute phase of an NSTI in consideration, 
a comprehensive analysis of existing or missing antibody titers and their protective 
potential in serum samples of NSTI patients would provide valuable insights into the 
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role of the adaptive immune system during the development of this dramatic infection. 
Therefore 3 distinct groups of serum samples of recruited INFECT cases were 
analyzed: NSTI cases that received an IVIG treatment (IVIG Treated Group), NSTI 
cases that did not received an IVIG treatment (Non IVIG Treated Group), and a control 
group of cases with severe skin and tissue infections, that did not develop into an NSTI 
(non NSTI cases/Control Group) and therefore also did not received any IVIG. The 
determination of antibody titers and their protective potential against the pathogenic 
bacterial cells as well as the bacterial toxins in these three groups would not only 
identify bacterial factors that play a crucial role in the development of the infection 
(NSTI cases versus non NSTI cases), but would also aid in elucidating the role of the 
serological state of the patient in the development of an NSTI. In addition, the 
comparison of IVIG-treated and non IVIG treated cases would decipher the 
effectiveness of IVIG as an adjunctive therapy. The study was therefore concentrated 
on 17 INFECT cases: 8 IVIG treated NSTI cases; 7 non IVIG treated NSTI cases and 2 
non NSTI control cases.  
During the course of infection, bacteria can pose certain antigenic challenges to the 
host, that, if targeted by specific antibodies indirectly contribute to an increased 
clearance of the bacteria by phagocytic cells of the innate immune system. Therefore, 
studying the presence of protective antibody titer in patient sera against the bacteria 
itself during the early stage of infection would identify risk factors towards an 
increased susceptibly of NSTI patients and would represent a first step into the 
development of an optimized IVIG treatment strategy. Therefore, Opsono-
phagocytosis assays were performed to determine if specific antibodies are present 
against expressed immunogenic proteins on the surface of the corresponding bacterial 
pathogen. These antibodies can boost the process of pathogen recognition with help of 
the complement system through clearance by Opsonization. To investigate if the 
antibodies against the bacteria itself would mediate efficient opsonization and 
subsequent killing, an opsono-phagocytosis assay was established using patient’s 
plasma that was collected on two different time points: Day 0, when a tissue infection 
was rated as NSTI and the patient recruited in the study, and Day 3, which was the 
third day of treatment after the NSTI was diagnosed. 
The establishment of a reproducible Opsono-phagocytosis assay implied certain 
mechanistic limitations. First of all, plasma components other than immunoglobulins 
and complement factors may also influence the process of bacterial opsonization113. To 
develop a suitable control system to address potential side effects of other plasma 
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factors a pool of commercially available human plasma was depleted from IgG by 
specific binding to Protein G Sepharose. This IgG depleted plasma was used on one 
hand as negative control but also in combination with a physiological amount of IVIG 
as positive control for bacterial opsonization. Secondly, due to the use of Li-heparin as 
anticoagulant in the experimental setup any factors of the complement system that are 
known to boost the opsonization and phagocytosis process in vivo are potentially 
excluded114. Therefore, all bacterial killing that is observed in the assay is potentially 
mediated by Fc receptor binding on the surface of the used phagocytic cells. 
Consequently, the real in vivo effect of the observed recognition and killing would be 
potentially higher than in vitro because of an active complement system The 
established Opsono-phagocytosis assay was validated with the INFECT isolate 2006, 
opsonized with IVIG in IgG depleted human plasma, which is known to potentially 
possess specific antibodies against S. pyogenes115. Interestingly, IVIG was able to 
mediate significant bacterial killing with respect to the growth controls. These results 
not only validated the functionality of the established Opsono-Phagocytosis assay but 
also proved the presence of antibodies reacting specifically against S. pyogenes isolates 
in the applied IVIG mixture. The established assay was extended to the complete set of 
selected INFECT isolates and their corresponding plasma samples. All NSTI cases did 
not show significant bacterial killing by human neutrophils when opsonized with Day 
0 plasma samples. Contrarily, a significant bacterial killing could be mediated with 
Day 0 plasma samples of the non NSTI control cases. These results point towards a 
potential susceptibility of the analysed NSTI patients due to a lack of IgG titers in their 
plasma that are able to mediate efficient killing of the corresponding S. pyogenes isolate. 
However, all NSTI cases, irrespective of the IVIG treatment, showed significant 
bacterial killing mediated by the Day 3 plasma samples. The treatment with IVIG was 
obviously able to enhance the bacteria killing as compared to Day 3 plasma samples of 
non IVIG treated cases, thus accounting for its enhanced efficiency to target bacteria 
probably due to presence of specific antibodies against the pathogen.  
The applied Opsono-Phagocytosis assay clearly showed an efficient reduction of 
bacterial counts mediated just by opsonization with plasma samples of NSTI and non 
NSTI patients, which are obviously carrying different antibody titers against the 
respective causative pathogen. Nonetheless, the antigenic presentation of the bacteria 
might vary significantly in vivo compared to the proteins presented in vitro (in THY 
media)116. Moreover, the bacterial capsule plays an important role in vivo, as it usually 
masks most of the exposed surface proteins by a thick Hyaluronic acid layer117. 
Hyaluronic acid is also a natural part of the host tissue and thus bacteria can easily 
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evade immunogenic responses. However, while growing in vitro (in THY), S. pyogenes 
downregulates the capsule118, exposing the bacterial-surface bound-antigens like M-
protein and SfbI that could lead to their enhanced killing while encountering human 
neutrophils.  
Out of all 15 analyzed INFECT NSTI cases, 14 showed a very similar pattern towards 
an efficient opsonization and subsequent killing of the causative bacterial pathogen 
only mediated by Day3 plasma samples. Possible explanations for this observation are 
either the applied IVIG administration or in case of the non IVIG treated patients a 
rapid adaptive immune response by an activation of already present Memory T-cells. 
Memory T-cells are generally activated on second encounter of a pathogen which leads 
to a rapid production of specific antibodies. Surprisingly, the plasma sample of one of 
the NSTI cases (INFECT 2015) was able to mediate significant bacterial killing already 
with the Day 0 plasma sample, which is in agreement with the results obtained with 
the developed serology ELISA system against the corresponding exotoxins. 2015 
closely resembled non NSTI cases with respect to titers and their protectivity. 
Unfortunately, due to the lack of detailed patient data, it is unsure if the patient 2015 
received the IVIG treatment before the Day 0 plasma collection or if 2015 is a kind of 
‘on the edge’ case, where the complex interplay between immune system and invading 
bacterial pathogen is located very close to the fine “borderline” that differentiates NSTI 
cases from non NSTI cases. This case also indicates that possessing a protective IgG 
titer against the invading bacterial pathogen is not the sole reason of not developing an 
NSTI. It is quite possible that phagocytic cells are unable to efficiently utilize the 
opsonization potential of the detected antibodies against the pathogen due to restricted 
oxygen pressure at the site of infection. Since the inflammation is immense, the blood 
supply to the necrotic site is hindered, leading to reduction in oxygen pressure and 
efficiency of phagocytic cells to eliminate the pathogen. To boost the oxygen pressure 
and on that way the activity status of immune cells, HBO is generally given as the 
adjunctive therapy and might not have been sufficiently provided. Other factors, like 
host HLA type119, general immune status, and underlying medical risk factors, should 
also be considered to be involved in the development of the infection. 
The applied Opsonophagocytosis assays revealed a significant susceptibility of the 
analyzed NSTI patients against the corresponding bacterial pathogen during the initial 
stage of infection whereas the data obtained from the analyses of the non NSTI control 
cases showed an IgG dependent protection potential in the Day 0 plasma samples. 
However, killing of the bacterial pathogen does not reduce their detrimental effects as 
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S. pyogenes is known to secrete a wide array of exotoxins20 that remain active and can 
further deteriorate the patient’s condition. Hence, the second aim of the study was to 
investigate the protective potential of an adaptive immune response against secreted 
bacterial toxins. Therefore, a comprehensive serology approach was applied, that 
should examine the question if specific antibody titers against all exotoxins encoded in 
the genomes of the causative bacterial isolate are present in the plasma samples of the 
selected INFECT patients and if these titers mediate efficient protection against the 
specific toxin function. This would elucidate if the absence of antibodies against a 
specific exotoxin or a group of exotoxins represents a risk factor in development of an 
NSTI.  
It is known that S. pyogenes secretes exotoxins that impair the host immune response in 
different ways like activation of non-specific T-cell sub-population (superantigens)120, 
cleavage of IgG (Mac)121, degradation of chemokines (spyCEP)122 or inactivation of 
complement factors (sic)123. Screening the genomes of all selected S. pyogenes INFECT 
isolates for the presence of various exotoxin genes would be the first step towards 
understanding the serological background of the selected NSTI cases towards the 
potential exotoxin repertoire of the causative pathogen. Therefore, a multiplex PCR 
was established that is able to detect 21 exotoxin genes in five separate reactions. The 
PCR genome screening of the selected S. pyogenes INFECT isolates showed that only 
some of the exotoxin genes were distributed in a serotype specific pattern, while other 
exotoxin genes like speB, speF, speG, scpA were always present; irrespective of the 
serotype of the bacteria. This could be indicative of their essential function in 
pathogenicity of the bacteria during the development of an NSTI. There are many 
previous researches that show similar exotoxin profiles of various M types124,125. 
Interestingly, sdc and sdaD were seen excluding each other; the former being present 
only in one of the isolates (INFECT 2015), which could represent a possible protection 
mechanism of S. pyogenes to eliminate redundancy in case of extracellular DNase 
activity. The resemblance matrix generated though the exotoxin gene repertoire clearly 
showed that the non NSTI isolates clustered together with the NSTI isolates, thus 
ruling out the possibility that NSTI cases carried a unique set of exotoxins that made it 
more virulent towards the development of a necrotic tissue infection like an NSTI. 
Since the occurrence and distribution of all known streptococcal exotoxins within the 
analyzed S. pyogenes INFECT collection was determined, the next logical step was the 
detection of antibody titers against the indicated exotoxins within the INFECT plasma 
samples. 
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As already mentioned, the host immune system eradicates the invading pathogen by a 
variety of mechanisms. The adaptive immune system helps boosting the process of 
pathogen recognition and clearance by the generation of specific antibodies. To 
investigate the contribution of the adaptive immune response by specific antibodies 
against streptococcal exotoxins in the NSTI scenario, all exotoxins identified by the 
applied PCR screening were either cloned, overexpressed and purified in an E. coli 
background or purchased if commercially available. An empty vector cloning batch 
was purified in parallel to address potential false positive readings induced by 
antibody titers against E. coli background contaminations. All variables possibly 
influencing the results of an ELISA system like antigen coating, primary and secondary 
antibody concentrations, ABTS concentrations, and the dynamic range of the detection 
system were sequentially standardized and a test experiment was performed using 
IVIG diluted in IgG depleted human plasma following the standardized procedure 
used in the Randomised Controlled Trial (INSTINCT) at Rigshospitalet Denmark 
(NCT02111161). This experiment clearly showed that the tested IVIG mixture contains 
specific antibody titers against all selected exotoxins, which, on one hand 
demonstrated the potential of the established ELISA system to detect antibody titers 
against streptococcal exotoxins, but on the other hand also proved the notion that IVIG 
contains specific antibodies against S. pyogenes exotoxins77. Extending the established 
ELISA system towards the  analysis of all selected INFECT cases illustrated the 
existence of only rare antibody titers against streptococcal exotoxins in the Day 0 
plasma samples, which were only increasing in the Day 3 samples independent of the 
IVIG treatment status of the patient. Contrarily, the plasma samples of the non NSTI 
cases showed significant antibody titers against the tested streptococcal exotoxins 
already at Day 0. Compiling the results of multiplex PCR screening with the data 
obtained with the ELISA system, it was obvious that all NSTI patients showed a 
potential susceptibility towards the exotoxin set present in the genome of the 
corresponding bacterial isolate during the early stage of infection. The administration 
of IVIG was able to increase the antibody titers against these exotoxin sets, proving the 
hypothesis that IVIG treatment potentially compensates a lack of specific antibodies 
against exotoxins of S. pyogenes. The non IVIG treated cases, showed an increase of 
specific antibody titers in the Day 3 plasma samples for only a few exotoxins. 
Especially the superantigens, SpeA, SpeG, SSA and SmeZ obviously seem to play a role 
in pathogenesis of S. pyogenes during development of NSTI as their titers increased 
significantly during the course of infection. This rapid antibody generation is most 
probably induced by a memory T-cell response of adaptive immune system. As 
mentioned earlier, the memory T-cells are generally activated on second encounter of 
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the pathogen and boost the production of specific antibodies rapidly so as to quicken 
up the annihilation of bacterial infection and neutralisation of secreted toxins. Other 
superantigens like SpeH, SpeI, SpeK, SpeL and SpeM did not seem to induce a 
detectable response of the host adaptive immune system, which can either be 
explained by a downregulation of these bacterial factors during the infection or by a 
lack of corresponding memory T-cells because the immune system of the patient was 
never before confronted with a streptococcal invader expressing this special setup of 
exotoxins. The second set of selected exotoxins includes various proteases, DNases and 
immune modulatory molecules. The antibody titers against SLO were seen to increase 
from the Day 0 towards Day 3 of infection in all non IVIG treated patients. SLO or 
streptolysin O, is an immunogenic cytolysin that ruptures the cell wall of host cells, 
thereby potentially causing failure of an immediate cellular immune response41. 
Streptokinase (Ska) is an important spreading factor of S. pyogenes that causes 
activation of Plasminogen by structural remodulation, which is subsequently able to 
dissolve fibrin clots thereby releasing bacteria entrapped in a thrombus probably 
induced by the initial injury51. Ska can be distinguished into three different classes on 
the basis of mechanism of plasminogen acquisition and activation: ska-1, ska-2a and  
ska-2b51. Sequencing the variable regions of ska revealed presence of only type 1 and 2a 
in the INFECT isolate collection. However, the established ELISA system was 
obviously not able to serologically differentiate between Ska-1 and 2b, as the variable 
region measures just 400 bp and might have lacked potentially accessible epitopes. In 
contrast to the analysed NSTI cases, the non NSTI control cases possess specific 
antibody titers against all exotoxins, for which the gene is present in the genome of the 
corresponding bacterial isolate already in the Day 0 plasma samples, which points 
towards a potential resistance of these patients against the development of an NSTI. 
Overall, the results obtained with the established ELISA system strengthen the 
hypothesis that a lack of specific antibodies against the causative bacterial pathogen 
and against corresponding bacterial toxins represents a risk factor for the development 
of an NSTI. The final step in the serological approach was to determine if the antibody 
titers, detected in the patient’s plasma, are able to mediate sufficient protectivity 
against the respective exotoxin. As a starting point all streptococcal superantigens were 
selected as a first subset of streptococcal exotoxins and hence, a T-cell proliferation 
Assay was established that would provide insights in the activity of the purified 
superantigens and the potential of the identified antibody titers to block the toxin 
function. 
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Antibodies against a particular exotoxin block its toxic effects by binding to its active 
sites, thereby neutralizing the toxin and providing ‘protectivity’ to the host. The 
selected set of eleven Streptococcal pyrogenic exotoxins possesses super antigenic 
properties, which means they target human T-cells in combination with antigen 
presenting cells, which leads to a non-specific activation of large amounts of T-cell 
populations. In the first test experiment all purified superantigens were able to induce 
a non-specific T-cell proliferation response that follows distinct concentration 
dependent patterns. Hence, the concentration wherein maximum T-cell proliferation 
was observed was selected for further experiments. As confirmed by the applied 
ELISA measurements, the used IVIG mixture carries significant antibody titers against 
all eleven superantigens, therefore, a first blocking experiment was performed with 
different concentrations of IVIG in IgG depleted human plasma. As expected, IVIG was 
able to block 100% of the superantigen activity with a concentration of as low as 20%  
(1 mg/ml), wherein all the superantigens were successfully blocked except SpeA. 
Interestingly, it was not possible to completely block the activity of SpeA, irrespective 
of the concentration of IVIG used, which is in accordance to previous reports104. One 
possible explanation that is discussed points towards additional domains of SpeA 
targeting the T-cells in a way that cannot be efficiently blocked by antibodies, because 
unlike other superantigens, SpeA binds to the MHC-II α chain instead of β126. The 
mechanism by which SpeA escapes the blockage by IVIG is still not known. The 
expansion of the T-cell Proliferation Blocking Assay analyses on a selection of INFECT 
cases clearly demonstrated the protective effect of the detected antibody titers against 
the superantigens. Comparing the results from the multiplex PCR screening and the 
ELISA based serology approach with the data obtained with the T-cell proliferation 
blocking assay, displaced a similar pattern wherein all detected antibody titers 
considered to be significant were protective and were able to inhibit the superantigenic 
properties of the exotoxins. This does not only indicate the authenticity of the ELISA 
system, but also the functionality of the established T-cell Proliferation Blocking Assay 
to detect and determine the protectivity of antibody titers. All detected antibody titers 
were able to block the superantigenic activity by more than 90%, except SpeA wherein 
inhibition above 80% was not possible. From the combined results of the Multiplex 
PCR screening, the serologic ELISA approach and the T-cell proliferation blocking 
assays, it is quite evident that the adaptive immune response plays a crucial role in 
development of an NSTI. These results can henceforth be extrapolated to other NSTI 
and non NSTI plasma samples. For the second set of exotoxins that consists mainly of 
proteases and DNases with different immune-modulating functions, it is still unsure if 
the antibody titers detected in patient plasma samples mediate efficient protection. 
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Specialized blocking assays, which will address this open question, will be established 
in extension of this study. 
The combined results of this study clearly show that the lack of protective antibodies 
against streptococcal exotoxins and against the bacterial cells itself represents a 
significant risk factor for the development of a severe NSTI. Whenever the pathogen 
(here S. pyogenes) enters the healthy individual, the interplay between the host immune 
system and the pathogen decides their fate of encountering an NSTI. There are many 
factors that contribute to whether the person would develop the disease or not. This 
study identified one of the crucial factors to be presence or absence of protective 
antibody titers in the patient and can help to bridge the time lapse between 
identification of the disease and its effective treatment. Rapid serological screening 
methods can be developed that will help in a quick and efficient screening of plasma 
samples of patients to estimate their susceptibility status towards the causative 
pathogen during the very early stage of a developing NSTI. In case the patient lacks 
antibody titers against the invading pathogen, IVIG can be provided at early stage of 
the infection development to restrict the progression. As shown by this study, the 
applied IVIG treatment is able to compensate the detected lack of protective antibody 
titers against streptococcal exotoxins and the bacteria itself and on that way eliminate 
this risk factor. However, time is a critical factor in this treatment. As the disease 
develops, inflammation at the site of infection escalates, which will affect the 
penetration rate of IVIG into the tissue. Hence, administration of IVIG needs to started 
as early as possible. Other adjunctive therapies like HBO can also help in boosting the 
protective potential of these antibodies by enhancing the oxygen supply at the site of 
infection. As seen in INFECT case 2015, the presence of protective antibodies alone 
does not suffice to prevent the development of an NSTI. Other factors, especially the 
general immune status of a patient should always be considered to be involved in the 
infection development. 
Although IVIG was seen to compensate the observed antibody titer deficiencies, its 
efficacy in clinical settings still remains questionable. Additionally, IVIG is a cost-
intensive therapy, usually accompanied by a variety of side effects. As the results of 
this study show the crucial role of the adaptive immune system, especially the 
serological background of a patient within the NSTI scenario, it can contribute towards 
development of more specific and targeted therapies and constitutes the first step 
towards the development of an improved NSTI treatment. 
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6.2 INFECT Case collection 
Patient  Identified 
Pathogen 
Isolated from 
Treatment Collection center 
No. Age Gender Co-morbidities NSTI IVIG HBO 
2001 67 M None Yes S. pyogenes Tissue Yes Yes 
Rigshospitalet, 
Copenhagen 
2002 64 M Hypertension tractatae Yes 
S. pyogenes 
Yeast 
Tissue Yes Yes 
Rigshospitalet, 
Copenhagen 
2003 47 F 
Fibromyalgia 
Short bowel syndrome 
Yes 
 
E. faecium 
E. sakazakii 
C. perfringes 
Yeast 
C. albicans 
 
Outer abdomen 
fluid 
Yes Yes 
Rigshospitalet, 
Copenhagen 
2004 73 F Hypertension tractatae Yes 
 
Actinomyces 
Yeast 
C. albicans 
 
Neck 
Blood 
Yes Yes 
Rigshospitalet, 
Copenhagen 
2005 59 M 
Diabetes 
Myocardial Infarction 
Yes E. faecium N.A Yes Yes 
Rigshospitalet, 
Copenhagen 
2006 62 F Hypertension tractatae Yes S. pyogenes Blood Yes Yes 
Rigshospitalet, 
Copenhagen 
2008 53 M HIV Positive Yes 
 
S. pyogenes 
Yeast 
C. albicans 
Pus 
Tissue 
Yes No 
Rigshospitalet, 
Copenhagen 
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2009 63 F None Yes 
 
Yeast 
C. albicans 
 
Blood Yes Yes 
Rigshospitalet, 
Copenhagen 
2010 66 M None Yes 
 
E. coli 
S. constellatus 
E. faecalis 
 
Tissue Yes Yes 
Rigshospitalet, 
Copenhagen 
2013 49 F Deep vein thrombosis Yes 
 
S. pyogenes 
Yeast 
S. aureus 
 
Tissue Yes Yes 
Rigshospitalet, 
Copenhagen 
2014 64 F Alcohol Abuse Yes E. coli N.A Yes No 
Rigshospitalet, 
Copenhagen 
2015 70 F 
C.Pulm 2012 
Smoker 
Yes S. pyogenes Blood Yes Yes 
Rigshospitalet, 
Copenhagen 
2016 77 F Hypertension tractatae Yes 
S. anginosus 
S. warneri 
N.A Yes Yes 
Rigshospitalet, 
Copenhagen 
2017 38 F None Yes S. pyogenes Tissue Yes Yes 
Rigshospitalet, 
Copenhagen 
3001 47 M Rheumatoid Disease Yes 
SDSE 
S. aureus 
N.A Yes Yes 
Karolinska  
University Hospital, 
Stockholm 
3003 38 F Hypertension Yes S. pyogenes N.A No Yes 
Karolinska  
University Hospital, 
Stockholm 
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3004 62 F None Yes 
S. pyogenes 
Staphylococcus 
N.A No Yes 
Karolinska  
University Hospital, 
Stockholm 
3005 65 F 
Chronic obstructive  
lung Disease 
Hypertension 
Yes S. pyogenes N.A No No 
Karolinska  
University Hospital, 
Stockholm 
3007 67 F 
Asthma 
Hypertension 
Yes S. anginosus N.A No Yes 
Karolinska  
University Hospital, 
Stockholm 
3008 69 F 
Diabetes 
Hypertension 
Yes 
S. epidermidis 
C. albicans 
N.A Yes Yes 
Karolinska  
University Hospital, 
Stockholm 
3009 85 M Hypertension Yes S. pyogenes N.A Yes Yes 
Karolinska  
University Hospital, 
Stockholm 
3010 73 F None Yes S. pyogenes N.A Yes No 
Karolinska  
University Hospital, 
Stockholm 
3012 42 F None Yes S. pyogenes N.A No Yes 
Karolinska  
University Hospital, 
Stockholm 
3013 58 M 
Chronic Obstructive 
Lung Disease 
Yes 
E. faecalis 
C. ramosum 
N.A No Yes 
Karolinska  
University Hospital, 
Stockholm 
3014 69 M 
Chronic Obstructive 
Lung Disease 
Yes 
 
E. faecalis 
B. fragilis 
 
N.A No Yes 
Karolinska  
University Hospital, 
Stockholm 
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3015 58 F Hypertension Yes 
E. faecalis 
E. coli 
N.A No Yes 
Karolinska  
University Hospital, 
Stockholm 
3016 66 M Hypertension Yes S. pyogenes N.A Yes Yes 
Karolinska  
University Hospital, 
Stockholm 
4001 N.A N.A N.A Yes 
E. faecalis 
S. saprophyticus 
N.A N.A N.A 
Blekingesjukhuset 
Karlskrona 
4002 N.A N.A N.A Yes 
 
E. coli 
S: milleri 
B. ovatus 
 
N.A N.A N.A 
Blekingesjukhuset 
Karlskrona 
4003 N.A N.A N.A Yes 
E. coli 
C. albicans 
N.A N.A N.A 
Blekingesjukhuset 
Karlskrona 
4004 N.A N.A N.A Yes 
 
E. faecalis 
C. albicans 
 
N.A N.A N.A 
Blekingesjukhuset 
Karlskrona 
4005 N.A N.A N.A Yes 
 
S. milleri 
C. perfringens 
E. coli 
 
N.A N.A N.A 
Blekingesjukhuset 
Karlskrona 
4006 N.A N.A N.A Yes 
S. milleri 
Lactobacilli sp. 
N.A N.A N.A 
Blekingesjukhuset 
Karlskrona 
5001 51 F 
Active Malignancy 
colon 
Yes C. septicum 
Blood 
Wound 
No Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
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5002 76 M Renal insufficiency Yes C. septicum Tissue No Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
5003 79 M 
Malignancy colon 
Atrial fibrillation 
Chronic left leg edema 
Yes S. pyogenes Blood Yes Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
5004 41 F None Yes S. pyogenes Wound Yes Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
5005 71 M None Yes SDSE Wound Yes Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
5006 37 M None Yes S. pyogenes 
Wound elbow 
Tissue right arm 
Wound right arm 
Yes No 
Sahlgrenska 
University Hospital 
Gothenburg 
5007 73 F N.A Yes S. constellatus Blood N.A Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
5010 68 M 
Pacemaker 
Artificial joint knee 
Yes 
S. aureus 
S. pyogenes 
Wound Yes Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
5011 65 M High Blood Pressure Yes S. pyogenes 
Blood 
Tissue 
Yes Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
5012 53 F Malign Melanoma Yes S. pyogenes Wound Yes Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
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5013 65 M 
High Blood Pressure 
Alcoholism 
Yes S. pyogenes Wound Yes No 
Sahlgrenska 
University Hospital 
Gothenburg 
5014 62 M High Blood Pressure Yes S. pyogenes Blood Yes No 
Sahlgrenska 
University Hospital 
Gothenburg 
5016 28 M Hepatitis C Yes 
S. massiliensis 
S. anginosus 
Tissue No Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
5017 53 M Diabetes mellitus type2 Yes S. anginosus Tissue No No 
Sahlgrenska 
University Hospital 
Gothenburg 
5019 52 M Asthma Yes 
E. coli 
Actinomyces 
Blood 
Wound 
No Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
5020 48 M None Yes S. pyogenes Tissue Yes Yes 
Sahlgrenska 
University Hospital 
Gothenburg 
6002 40 M Hepatitis C Yes 
Enterobacter sp. 
Actinomyces 
Upper Leg No No 
University of Bergen 
Bergen 
6003 48 M None Yes S. anginosus Blood No Yes 
University of Bergen 
Bergen 
6004 55 M None Yes S. pyogenes Upper Leg No No 
University of Bergen 
Bergen 
6005 54 M Diabetes mellitus Yes S. aureus Blood No No 
University of Bergen 
Bergen 
6006 28 M Active Malignancy Yes 
SDSE 
S. aureus 
Thorax No Yes 
University of Bergen 
Bergen 
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6007 57 F Blunt trauma Yes SDSE Lower Leg No No 
University of Bergen 
Bergen 
6008 48 M 
Hepatitis C 
Blunt trauma 
Yes E. coli Blood No No 
University of Bergen 
Bergen 
6009 71 M 
Cardiovascular 
Disease 
Yes E. coli ESBL Upper Leg No No 
University of Bergen 
Bergen 
6010 62 F Asthma Yes E. coli Infected Site No No 
University of Bergen 
Bergen 
6012 46 M None Yes 
E. coli 
S. milleri 
Blood No No 
University of Bergen 
Bergen 
6013 34 F None Yes S. pyogenes 
Blood 
Neck 
Yes Yes 
University of Bergen 
Bergen 
6015 37 M 
Hepatitis C 
Drug User 
Yes 
Gram Negative 
species 
Upper Leg No No 
University of Bergen 
Bergen 
6016 41 M None Yes S. pyogenes Elbow aspiration No No 
University of Bergen 
Bergen 
6017 72 M 
Kidney Failure 
Liver Failure 
Yes SDSE 
Blood 
Leg 
No No 
University of Bergen 
Bergen 
6018 39 F None Yes S. pyogenes Axilla No No 
University of Bergen 
Bergen 
6020 61 M 
Cardiovascular 
Disease 
Yes SDSE Axilla No No 
University of Bergen 
Bergen 
 
Appendix 
 
118 
 
6023 54 F 
Operated Breast 
cancer 
Yes S. aureus Infected Site No No 
University of Bergen 
Bergen 
6025 37 M Psoriasis Yes S. pyogenes Infected site No No 
University of Bergen 
Bergen 
6026 48 M None Yes S. pyogenes Infected site No No 
University of Bergen 
Bergen 
6028 41 M None No S. pyogenes Infected site No No 
University of Bergen 
Bergen 
6029 62 M 
Alcohol Abuse 
Chronic ulcer 
Yes 
S. pyogenes 
S. aureus 
Infected Site No No 
University of Bergen 
Bergen 
6030 69 M Hypertension Yes 
S. aureus 
S. epidermidis 
Infected Site No Yes 
University of Bergen 
Bergen 
6031 74 M Hypertension Yes S. aureus Blood culture No No 
University of Bergen 
Bergen 
6032 54 M Anal Cancer Yes 
SDSE 
S. haemolyticus 
Infected Site No No 
University of Bergen 
Bergen 
6033 50 F None Yes S. pyogenes upper extremity No No 
University of Bergen 
Bergen 
6034 43 M None Yes S. pyogenes Blood No No 
University of Bergen 
Bergen 
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6035 23 M Alcoholism Yes 
E. coli 
Citrobacter sp. 
Infected Site No No 
University of Bergen 
Bergen 
6036 37 M Malignant melonoma Yes SDSE Blood No No 
University of Bergen 
Bergen 
6037 80 F 
Cardiovascular 
Disease 
Yes SDSE Blood No No 
University of Bergen 
Bergen 
6038 60 M 
Cardiovascular 
Disease 
Yes 
S. pyogenes 
S. aureus 
Upper Leg No No 
University of Bergen 
Bergen 
6039 59 F Psoriasis Yes S. pyogenes Blood Yes No 
University of Bergen 
Bergen 
6040 32 F None No S. pyogenes Upper Leg No No 
University of Bergen 
Bergen 
6041 27 F Recent dentist surgery Yes S. milleri Neck No Yes 
University of Bergen 
Bergen 
6042 31 M Recent dentist surgery Yes 
S. anginosus 
S. intermedius 
Neck No Yes 
University of Bergen 
Bergen 
N.A: Not Available 
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6.3 Ethical Permissions 
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Ethical Permit Number 
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Hospitals:  
Stockholm, Sweden 2006/321-31/4 and 2012/2110-31/2 
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Gothenburg, Sweden 930-12 
Bergen, Norway 2012/2227/REK vest 
  
 
 121 
 
Acknowledgment 
It is not the happy people that are thankful; 
It is thankful people who are happy 
                       -Anonymous 
There is indeed a long list of people I wish to be thankful to, who have helped me 
achieve this difficult goal of my life. I hope I can cover them all in this limited space: 
First of all, I would like to thank Prof. Dr. G. S. Chhatwal, who gave me an 
opportunity to come all the way from Delhi to Braunschweig and work under his 
guidance on the fascinating pathogen S. pyogenes.  
I would also like to thank Prof. Dr. Dietmar Pieper, who warm heartedly ‘adopted’ us 
after our old group disintegrated. His friendly and enthusiastic behavior had always 
motivated me to work hard. 
I would like to specially thank my supervisor Dr. Andreas Itzek. Any amount of 
gratitude would fall less in exchange of how big his support has been. I owe my 
successful PhD to him as he had always been the ‘guiding star’ from the first day here 
to the days I tortured him while writing my thesis. He is indeed a perfectionist and I 
wish I could be like him one day!  
I am also thankful to Prof. Dr. Sussanne Engelmann and Prof. Dr. Michael Hust for 
being my second referee and chair for the doctoral examination respectively. I thank 
Dr. Oliver Goldmann and Prof. Dr. Marcus Fulde for being my thesis committee 
members and providing their useful suggestions and guidance for my project. 
I am obliged to all the clinical partners for sending the samples timely and safely. The 
great work of Rigshospitalet (Copenhagen), Karolinska University Hospital 
(Stockholm), Sahlgrenska University Hospital (Gothenburg), Blekingesjukhuset 
(Karlskrona) and University of Bergen (Bergen) is beyond appreciation.  
I owe my special ‘Thank you’ to all the members of groups of Medical Microbiology 
(MMIK) and Microbial Interactions and Processes (MINP) for being friendly, 
cooperative and providing me with the feeling of Braunschweig being my second 
home. Thank you Rene, Patric, Israel, Domenica, Giuseppe, Christin, Katharina, 
Naveen, Sarah, Katja, Astrid, and all others that I fail to mention here. 
 122 
 
I would not forget to mention a special thank you for Imran Rahim, who has been my 
friend, my companion and my ‘partner in all crimes’. He has always been a support- 
from preparing tasty ‘Indian food’ to giving his suggestions while I was writing my 
thesis.  
My friend and sister Rimpy Chowhan, thanks for being there as a constant wall of 
support. She has always been there, in my thick and thins and ensured everything 
is/will be fine.  
My ‘thank you list’ would be incomplete without the mention of my family, who 
bestowed their faith in me and sent me thousands of miles away from them to fulfil my 
dream. I am thankful to my dad Mr. Naresh Babbar and my mom Mrs. Alka Babbar. I 
love you both and I would have been nothing without your perseverance and patience. 
My little brother Ankush Babbar, thanks to you too, without you I would have missed 
the fun of being the elder sister! 
At the end, I would like to thank God for bequeathing me with so many blessing in 
form of my family, friends and teachers. 
Thank you all 
 
Anshu Babbar   
 
 
 
